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ABSTRACT

Aortic Valve Bypass surgery has found renewed interest to researchers due to its
application in high-risk patients with severe aortic stenosis. This therapy consists of
construction of a conduit containing a bioprosthetic or mechanical valve from the apex of
the left ventricle to the descending thoracic aorta. Blood is ejected from the left ventricle
via both the native stenotic aortic valve and the conduit. This thesis proposes a design for
one of the least developed components of this system, the cannula component that sits
inside the left ventricle and allows for flow of blood from the left ventricle and into the
conduit. Experimental use of mock flow loop testing and computational flow dynamics
analysis (ANSYS Inc., Canonsburg, PA, U.S.A.) on prototype and currently used clinical
venous cannulas were used in the development and design of the proposed apical
cannula. Aortic valve bypass results in a low gradient across the native stenotic valve and
a small gradient across the conduit. The results from the mock loop experiments, CFD
analysis, clinical data, and findings from previous researchers have aided in design of a
new apical cannula. It is hoped that this cannula will be a more favorable design over
currently used apical connectors. Further in vitro and in vivo studies are needed to
validate these results.
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I. INTRODUCTION
Treatment of aortic stenosis through surgical replacement has been one of the
most successful advances in cardiovascular medicine and has increased the quality of life
for patients worldwide (1). However, use of this technique in certain patient populations,
specifically the elderly, has been associated with increased mortality rates (2). A growing
alternative therapy for these populations is implantation of Aortic Valve Bypass (AVB)
(3). In simplest terms, this alternative creates a second path for blood ejected from the left
heart by creating a one-way conduit between the apex of the left ventricle and the
descending aorta. The overall resistance of the blood being pumped to the rest of the
body is thereby decreased by the creation of two paths to follow.
The AVB system consists of three main components: a bioprosthetic or
mechanical valve, an apical cannula inserted into the left ventricular apex, and bypass
conduit material connecting these components. Blood is ejected from the left ventricle via
both the native stenotic aortic valve and the AVB conduit. The advantages of AVB lie in
the decreased surgical risks as compared to conventional aortic valve replacement (AVR)
in high-risk patient population pools. AVR requires cardiopulmonary bypass, ascending
aortic crossclamping, aortotomy, debridement of the diseased valve, and cardioplegic
cardiac arrest which are all avoided in the AVB surgical approach.
The focus of this report is on the design and testing of a critical component in the
AVB system, the apical cannula inserted into the apex of the left ventricle. There has
been much research devoted in the past into the development of the valve and conduit
design (2,4,5). Design and testing of artificial heart valves for surgical replacement have
been refined over the course of over 4 decades while research on conduit materials have
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increased with the advent of Ventricle Assist Devices (VAD). Though, currently there is
little research on the optimization of the apical cannula at the insertion point of the
conduit.
Important factors in creation of the cannula include the tip design, inlet diameter
size, number of sideholes, and flow profile. The novel aspects of the proposed design are
in the use of Pyrolitic Carbon (PYC) for fabrication and the modified Seldinger surgical
implantation technique used (6,7). PYC has been used for decades in prosthetic valves
and shows significant biocompatibility in the body. The modified Seldinger technique
provides a simple and quick insertion procedure designed to decrease operating time and
improve patient outcomes.
A series of experiments was completed to shape the design and characteristics of
the prototypes. This includes use of mock flow loop testing and Computational Flow
Dynamics (ANSYS Inc., Canonsburg, PA, U.S.A.). Mock loop testing was performed at
the Cardiovascular Innovation Institute in Louisville, KY. The cannula was produced
with the use of CAD modeling (SolidWorks SP3.0, Dassault Systèmes; Vélizy, France)
and employed the use of a proprietary manufacturing process for fabrication (ATS
Medical; Minneapolis, MN). This report presents a design of an apical cannula for use in
aortic valve bypass. Further experimentation and animal studies will be needed in future
development of this promising technology.
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II. OBJECTIVES
The main objective of this work is the design of a new apical cannula to be used
in the AVB system. This was accomplished by testing of a series of clinically available
cardiopulmonary bypass venous cannulas, a prototype cannula, and CFD analysis of
computer generated cannula models. The end result of this testing is a new proposed
apical cannula presented in Section X.
Section III provides a background into aortic valve bypass and details the benefits
of AVB over AVR in high risk patient populations. Section IV details the design process
followed in the development of the cannula, as well as the novel aspects, properties, and
techniques associated with the cannula. This section also presents the preliminary
prototype, a cannula produced for testing.
Sections V, VI, and VII describe the methods, instrumentation, and the results,
respectively, of experiments performed on the cannulas. These testing methods included
three flow loop experiments and CFD analysis. Section VIII discusses the results of the
experiments and provides insight into the properties of the cannula. Section IX wraps up
the work with conclusions and ideas for future work. The final section, based from the
conclusions of the experiments, presents a final design for an apical cannula proposed
Section X.
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III. BACKGROUND
The aortic valve is a semilunar, tricuspid valve positioned between the aorta and
left ventricle at the end of the left ventricular outflow tract. The normal working of this
valve is critical to maintaining efficient cardiac function. During ventricular systole,
pressure rises in the left ventricle. When the pressure in the left ventricle rises above the
pressure in the aorta, the aortic valve opens, allowing blood to exit the left ventricle into
the aorta. When ventricular systole ends, pressure in the left ventricle rapidly drops and
the aortic pressure forces the aortic valve to close.
The opening and closing of the aortic valve is a passive mechanism responding to
the pressure fluctuations of the cardiac cycle, particularly the pressure differences
between the left ventricular chamber and the aorta. Although pressure changes during the
cardiac cycle may create some structural changes in the valve mechanism to facilitate
opening or closing, the principal component of valvular function is the pressure
difference between the left ventricle and the aorta. (8)

Aortic Stenosis
Aortic Stenosis (AS) is the narrowing of the native valve controlling blood flow
between the left ventricle and aorta in the heart. As the valve narrows, it impedes the flow
of blood to the rest of the body and can lead to a host of physiologic complications,
including congestive heart failure. When the aortic valve becomes stenotic, it causes an
increase in the pressure gradient between the left ventricle (LV) and the aorta during
systole. The more constricted the valve, the higher the pressure gradient between the LV
and the aorta. Figure 1 shows the differences between normal and stenotic valves.
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FIGURE 1 - Location of Aortic valve in the heart which controls the flow of blood from
the left ventricle to the Aorta (left). Transverse view of a normal aortic valve seen from
the top (center). Similar view of a stenotic aortic valve (right).

AS is the most common of valvular defects and develops mainly in the elderly
population (9). It is primarily caused by three conditions: congenital defects,
calcification, or scarring caused by disease.
The most common source of AS of the three main causes is degenerative
calcification of the aortic valve. This is a condition where large calcium deposits form on
the aortic valve leaflets. Over time the leaflets will harden and thicken, a condition called
aortic sclerosis, which will develop into AS. Although previously considered to be the
result of years of mechanical stress on an otherwise normal valve, it is now believed that
the degenerative process leads to inflammatory changes, with lipid accumulation,
upregulation of angiotensin converting enzyme (ACE) activity, and infiltration of
macrophages and T lymphocytes ultimately leading to calcification of the aortic valve
(10).
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Congenitally, many patients are born with a bicuspid or a unicommissural aortic
valve, an anatomic variant which the aortic valve consists of one or two leaflets that
frequently evolves into stenosis. Bicuspid aortic valves are present in approximately 2%
of the general population (10). Gradual calcification of the bicuspid aortic valve results in
significant stenosis most often with patients in their late 50’s or 60’s. This becomes more
prevalent earlier in unicommissural than in bicuspid valves and earlier in men than in
women. The underlying causing the development of AS in these patients is due to the
abnormal architecture of the unicommissural or bicuspid aortic valve which induces
turbulent flow. Turbulent flow injures the leaflets and leads to fibrosis, increased rigidity,
leaflet calcification, and narrowing of the aortic valve orifice.
The last main cause in the development of AS is scarring of the heart’s aortic
valve which is caused by a number of factors. A large number of AS cases in the past
arose from scarring induced from rheumatic fever. Rheumatic AS currently represents the
least common form of AS in the adult population and usually occurs in conjunction with
mitral valve stenosis (1). Rheumatic AS is characterized by diffuse fibrous leaflet
thickening of the valve with fusion to a variable extent of one or two commissures.
Overall distribution of causes of AS varies significantly among different age
groups. Among patients younger than 70 years of age, congenitally calcified bicuspid
valves were responsible for half of surgical cases. Though, in patients over 70 years of
age, degenerative calcific stenosis is the most prevalent cause of stenosis. The prevalence
of AS is growing rapidly within the aging population of the United States. Nkomo et al.
completed a population based study with over 12,000 randomly selected adults from the
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general population (11). They noted that moderate or severe valvular diseases are
common and increase with age as seen in Figure 2.

FIGURE 2 - Prevalence of valvular disease in general population based on age. Note the
steep increase in prevalence rate in those 65 years of age and older.

Classification Criteria for Aortic Stenosis
Surveillance of the aortic valve for calcification and deterioration of the AS
monitored by jet velocity, measurement of aortic valve area, and transvalvular pressure
gradient are important clinical factors in identifying populations of AS patients at risk.
The severity of AS is assessed by estimating the mean systolic gradient and aortic valve
area (AVA). In 2006, the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (ACC/AHA Practice Guidelines) published a report
outlining the definition and care for valvular diseases (12). A classification of severity
that incorporates 3 measurable factors in AS was proposed. Estimation of aortic valvular
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area and maximum aortic velocity of the blood column during systole, as well as peak
and mean pressure gradients across the stenotic valve can be achieved using Doppler
echocardiography and pressure catheter measurement.
In these guidelines, AS is graded as mild for AVA greater than 1.5 cm2, moderate
for areas between 1.0 and 1.5 cm2, and severe for a valve area less than 1.0 cm2. The
criteria for mild, moderate, and severe AS, when analyzing measured jet velocity in
meters per second, are less than 3.0, 3.0 to 4.0, and greater than 4.0, respectively. The
transvalvular pressure gradient is best measured with a catheter in the left ventricle and
another in the proximal aorta.
The peak-to-peak gradient is measured as the difference between peak left
ventricular pressure and peak aortic pressure and commonly used to quantify the valve
gradient. A mean gradient across the aortic valve of less than 25 mm Hg is classified as
mild AS, severe AS is defined by a mean pressure drop greater than 40 mm Hg, and
moderate AS lies between mild and severe. Most patients with AS have surgery when the
AVA is less than 0.7 cm2 or there is a mean systolic gradient of more than 50 mm Hg,
though patients may become symptomatic sooner and require AVR before these
thresholds are reached (9).

Current Treatments for AS
To date, there is no conclusive evidence to support optimal medical management
of AS and in the past have shown dismal prognosis for patients (9). Rosenhek and
colleagues identified 128 consecutive patients with severe AS with an aortic jet velocity
of 5.0 +/- 0.6 m/s and followed them prospectively for 22 +/- 18 months (13). An event
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was defined as either death (8 patients) or surgical replacement (AVR). At one year twothirds of the patients remained event free, and by four years only a third remained event
free. Of those patients whose aortic jet velocity increased by more than 0.3 meters per
second per year, 80% died or underwent AVR within 2 years. The severity of aortic valve
calcification was an independent predictor of event-free survival. Absence of or minimal
valvular calcification predicted a 75% event-free survival at 4 years. Only 20% of those
with moderate to severe calcification remained event free at 4 years (13).
A larger study of 622 patients with severe, asymptomatic AS as defined by a peak
jet velocity of greater than 4 m/s were completed by Pellikka and colleagues (14). At 5year follow-up only 25% of the patients remained free of surgery or cardiac death and
only one-third remained symptom free. One-third of patients developed cardiac
symptoms of angina, syncope, or dyspnea before surgery within 2 years. They identified
a statistical risk of sudden death of approximately 1% per year in un-operated patients
(14). In large part due to data published, the ACC/AHA Practice Guidelines (12) have
said, ‘‘there are no medical treatments proven to prevent or delay the disease process in
the aortic valve leaflets.’’ It seems the best treatment option for patients with severe AS is
a surgical intervention, which most commonly is through aortic valve replacement
(AVR).
Alternative therapies include new developments in percutaneous deployment of
aortic valves in stents (percutaneous aortic valve replacement, PAVR) and a revival of a
surgical treatment known as an aortic valve bypass (AVB). There are two approaches to
PAVR, an antegrade and retrograde approach, which have seen some success in high risk
patient groups (9). PAVR is still in its experimental stages and carries significant risks,
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though its potential as an alternate therapy is very promising. The techniques proposed in
this thesis work advocate the use of aortic valve bypass for treatment in high risk patients.

Aortic Valve Replacement
The current and most routinely used treatment for severe AS is aortic valve
replacement (AVR). Since its first use in 1961, the basic procedure has remained
unchanged and over 180,000 procedures are now performed annually worldwide (15).
The procedure for AVR surgically removes the patient’s stenotic aortic valve and
replaces it with either a bioprosthetic valve or a mechanical valve. AVR commonly
demands the use of cardiopulmonary bypass, ascending aortic crossclamping, aortotomy,
debridement of the diseased valve, and cardioplegic cardiac arrest; it therefore carries a
finite risk of morbidity and mortality.
Outcomes after conventional AVR, although clearly superior to untreated AS,
remain imperfect. Table I shows recent data from the 2008 Society of Thoracic Surgeons
(STS) database. Operative mortality remains fairly low at 4%, but increases with high
risk patient groups. Although operative mortality is an important outcome for any
therapeutic intervention for aortic stenosis, it is also important to consider the morbidity
associated with cardiac surgery.
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TABLE I
STATISTICS FOR AVR, SOURCE: STS DATABASE 2008.
AVR Statistics

Mean

Age

66 Years

Reoperation

17%

Cross-clamp time

80 min

Perfusion time

110 min

Operative Mortality 4%

In the 2001 STS report, the risk for stroke was 1.58%, renal failure 3.70%, and
reoperation for bleeding 4.12% (2). Figure 3 shows that survival rates decrease with age
(16). One report shows that for patients 80 years of age and older undergoing AVR, the
immediate mortality is 10% (17). The risks of operative conditions increase the morality
rates in the high-risk elderly population, though this treatment is comparatively better
than no intervention.

FIGURE 3 - Long term survival rates for AVR for over 13,000 patients as published by
Blackstone et al.
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Despite the mortality, the number of patients older than 80 years undergoing AVR
is significant. As the population ages, and without an alternative therapeutic option,
surgery in these high-risk patients continues (9). For patients with severe AS who refuse
surgery, the average survival is 2 years or less (18). Of the octogenarians surviving the
initial postoperative period of 60 days, two-thirds survived 3 years or longer, and 40%
were alive 5 or more years after surgery (17). Because symptomatic AS is an indication
for surgery, alleviation of symptoms postoperatively is a factor in assessing surgical risk
and benefit. In the elderly, relief of symptoms may be of even greater importance than
long-term survival data. Patients and physicians alike are therefore willing to undertake
AVR even in light of significant immediate mortality (9).

Aortic Valve Bypass
The surgical treatment of AS with Aortic Valve Bypass is not a new idea and has
been around for 45 years. Aortic valve bypass (AVB; apicoaortic conduit) surgery
relieves AS by shunting blood from the apex of the left ventricle to the descending
thoracic aorta through a valved conduit (Figure 4). The idea was first conceived by Carrel
in 1910 (4), performed experimentally by Sarnoff in 1955 (19) and had first clinical use
by Templeton in 1962 (20). This technique has been almost exclusively used in the highrisk AS population.
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FIGURE 4 - Diagram of Aortic Valve Bypass system currently used. Blood is shunted
from the left ventricle into the descending aorta.

For some high risk patients, more exclusively in the elderly population, AVB is
an important alternative surgical therapy offering distinct advantages over AVR. The
main advantages include avoidance of sternotomy, cardiopulmonary bypass, cardioplegic
arrest, native valve debridement, conduction system injury, aortic cannulation, and aortic
cross-clamping. Another advantage to clinicians, particularly over percutaneous
approaches, is the ability to use a known commercially available prosthetic valve with a
strong track record for durability (21). Surgeons are able to mix and match approved
valves and components in the assembly of the AVB system to suit the patient and
procedure used.
Gammie et al. performed a retroactive chart review of AVB and reported that this
type of treatment is promising in nature and believe the basic configuration of the system
to be brain protective (22). Blood flow to the brain comes from the stenotic valve while
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the rest of systemic flow is delivered from the aortic bypass. Any potential thrombi
spawned from the prosthetic valve are carried downstream to the descending aorta
thereby lessening the chances for stroke. Gammie, et al. provided evidence for this in a
clinical review of AVB (Table II), which demonstrated complete absence of late stoke
among hospital survivors of the surgery.
Clinically, the same group has recently achieved very positive results in using
AVB (3). They found that the mean systolic gradient across the native aortic valve
decreased from 43 to 10 mmHg and echocardiographically determined conduit flow
(expressed as a percentage of total cardiac output) was 72%. Approximately one third of
blood flow went through the native stenotic valve and two thirds via the conduit. They
hypothesize that the distribution of blood flow after AVB surgery protects the brain from
thromboembolism arising from the prosthetic valve because no blood flow to the brain is
derived from the conduit. They concluded that this may contribute to a decrease in both
perioperative and long-term stroke risk after AVB surgery compared with conventional
AVR (3).
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TABLE II
REVIEW OF CLINICAL EXPERIENCE WITH AORTIC VALVE BYPASS.

A) Eighteen of 23 done without CPB; 18 of 23 were reoperations; 2 deaths in children with complex congenital problems; 2 deaths in
patients in cardiogenic shock; 1 technical problem (80-year-old patient with friable ventricle: bleeding contributed to death); used 20
to 22 mm conduits for adults [22]. B) Both deaths in high-risk patients; left ventricle connector size range 14 to 20 mm [5]. C) 8 late
deaths; 4 shunt-related (3 disruption of conduit from LV, 1 infection); 26 long-term survivors all asymptomatic, none on
anticoagulation, none with thrombembolism; in subgroup of patients 65 and older, 6 of 7 were alive and well an average of 5 years
postoperatively [12]. D) One death due to postoperative sepsis. Patient 2, 19 years out without symptoms, has had two babies; 3
patient had conduit thrombosis due to heavily calcified tissue valve 6 years out, underwent successful reoperation (valve replacement
in conduit) and died at 13 years (suicide). Patient 4 required similar valve replacement 3 years postoperatively, now 15 years out and
doing well [15]. E) All cases done off-pump [11]. F) No thromboembolic complications related to the conduit were observed among
hospital survivors.

The benefits of AVB over AVR for high risk patients are numerous, though there
are still potential problems with the operation. Some of these problems include
pseudoaneurysm, difficulty with the aortic anastomosis in a highly calcified descending
aorta, kinking of the conduit, and possible dislodgement of LV apical thrombus that was
not visible in preoperative or intraoperative imaging. The surgeon may also have
difficulties in the early adoption of this technique. Some of these problems include
experience trouble with bleeding due to lack of control of the left ventricular apex of the
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heart and possible use of femoral cardiopulmonary bypass which adds risk of
embolization. Though as Gammie et al. explain, once the initial learning curve is
surmounted the surgeon should be able to perform the operation quickly, safely, and
without the use of cardiopulmonary bypass (3).

Currently Used Design and Materials
There are 3 typical components used for this operation: (9) a rigid apical
connector with a right-angle bend constructed of polypropylene that surrounds a woven
Dacron graft and is covered with knitted Dacron and includes a sewing ring; (10) a
prosthetic valve or mechanical valve (stentless porcine valves are the most commonly
used valves); and (4) a straight woven Dacron vascular graft as shown in Figure 5. There
are few industry-produced apparatus used for AVB surgery and as such it is often
common for institutions to mix and match grafts, conduits, and connectors to suit their
surgical technique. As this technique is further developed and used, further development
of available materials is expected. Description and commonly used materials of these
three components are given as following.
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FIGURE 5 - Diagram of Aortic Valve Bypass system currently used. System consists of:
A - Elbow apical connector, B – Prosthetic or mechanical valve, C - Straight woven
Dacron vascular graft. (23)

1) Apical connector – Animal laboratory work done by Brown et al. demonstrated
that a semi-rigid stent was necessary to prevent progressive narrowing of the apical left
ventriculotomy (23). Direct application of a prosthetic graft to the apical myocardium has
been reported and resulted in obstruction at the ventriculotomy site (24). A curved left
ventricular connector or stent is supplied in sizes from 12 to 22 mm by Medtronic, Inc.,
(Figure 6).
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FIGURE 6 – Right angle apical connector manufactured by Hancock- Extracorporeal
(Hancock, Medtronic Inc., Minneapolis, MN) (25).

The connector was developed in the early 1970s by Hancock- Extracorporeal
(Hancock, Medtronic Inc., Minneapolis, MN) for Brown, et al., (20) and has been
continually supplied since that time. It was originally supplied in both straight and angled
configurations, though is routinely used as the right-angled connector for aortic valve
bypass done through a left thoracotomy. The 90° angle in the stent prevents kinking of
the conduit. The apical connector is designed to project 3 to 10mm into the cavity of the
left ventricle. It is lined with a low-porosity woven graft and its external surface is
covered with a more porous graft material to promote tissue ingrowth (23).

2) Prosthetic or mechanical valve – Either type of valve may be used, and their
usage depends on the institution performing the operation. Due to widespread use and
development of AVR, the design and safety of replacement aortic valves have been
refined and improved for decades. The sizes range from 17 to 23mm as appropriate to the
patient and procedure. Currently, the valves used in most institutions for AVB are
prosthetic with the most common being the stentless porcine valve. The advantages of
prosthetic valves lie in the postoperative treatment of patients. Mechanical valves require
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anticoagulation drugs, such as Coumadin, which increase the risk for stroke. With use of
prosthetic valves, physicians can treat patients postoperatively with just aspirin.
It is also possible to obtain valved conduits on the market that simplify the work
of the surgeon as the valve and the vascular graft are preassembled. Currently, the only
FDA approved commercially available valved conduit is manufactured by Medtronic,
Inc. (Minneapolis, MN) seen in Figure 7.

FIGURE 7 – Example of valved conduit used in the AVB system produced by
Medtronic, Inc (25)

The conduit contains a stentless porcine aortic valve that is glutaraldehyde
preserved and has an estimated valve area of 3 cm2. It comes in sizes of 12 to 22 mm in
diameter, which can be used for almost any size patient. The valve in the conduit is
positioned between the proximal and middle third of the conduit. This position of the
valve allows room for placement of vascular clamps, when or if the conduit valve
replacement is needed in late follow-up. (23)
3) Straight woven Dacron vascular graft – Awoven Dacron graft produced by
Hemashield, Boston Scientific, Natick, MA is the most commonly used graft Surgeons
use this graft material for many different clinical applications, including shunts, valves,
and cannula (25). The length and size of the graft is custom suited to the patient.
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Current Implantation Technique
Implantation of the AVB conduit system is commonly performed through either a
median sternotomy or lateral thoracotomy. The left thoracotomy is the most common
approach , particularly if the patient has had prior sternotomy(s). The thoracotomy
procedure has been well described by a number of physicians (5,23,24). The procedure
can be done without crossclamp and hypothermic circulatory arrest, and requires
markedly less time on cardiopulmonary bypass. Most importantly, the risk of
perioperative stroke is significantly reduced decreased (25).
A currently used ‘off pump’ procedure, as described by Vassiliades (5), uses an
18-gauge needle inserted through the left ventricular apex. A guide wire and a series of
dilators are then applied to the ventricular apex and a 14 Fr occlusion balloon is inserted
over the wire. A ventricular coring device is then threaded in-line over the catheter, and
the apical core is removed. The balloon occludes the apical opening in the ventricle while
the connector is slid into place. The occlusion balloon is left in place while sutures are
sewed from the ventricular muscle around the opening in the apex to the external cuff of
the connector. The distal end of the apical connector is then sewed to the valved conduit
and de-aired (5).
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IV. DESIGN AND CONCEPT

Evaluation Process
As previously discussed, the aortic valve bypass system is favored by many
clinicians due to the established track record of their individual components (i.e. graft,
valve, apical cannula). Specifically, prosthetic valves have a long history and have been
successfully used clinically for decades. In contrast, the apical cannula used for AVB has
not been extensively studied. The design of the current apical connectors is an adaptation
from a design primarily used for complex congenital left outflow tract obstruction in
children (3). As such, optimization of the design of the apical cannula could improve
flow characteristics of the entire system.
There are a number of important evaluation criteria when developing the apical
cannula (Table III). These important design points include the size of the conduit,
biocompatibility, optimal tip design, surgical insertion technique, stagnation points, and
blood hemolysis/shear stresses. Other important design criteria include the type of blood
flow, amount of retrograde flow, and adequate blood flow to the aortic arch head vessels.
The upper and lower limits for the size of the cannula are governed by two
factors. The upper limit is defined by the surgical insertion technique used. The lower
limit is the smallest size that will allow adequate blood flow through the conduit with low
aortic valve pressure gradient. To discern these design end-points, a series of in vitro
experiments with a mock circulation flow loop were conducted, which were then
validated in a computational flow dynamic (CFD) model.
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TABLE III
DESIGN CRITERIA FOR THE DEVELOPMENT OF THE APICAL CANNULA
Mock Flow Loop
Experimental Design Criterion

Dynamic
Flow

Static
Flow

X

X

Size of the conduit
Biocompatibility of materials
Optimal tip design
Stagnation areas / eddies (thrombosis)
Blood Shear Rate / Hemolysis
Type of flow (laminar or turbulent)
Amount of retrograde flow
Flow to coronaries and head vessels
Surgical Insertion Technique

Blood
Trauma

Computational
Fluid Analysis
(CFX)

Animal
Model
(bovine)

X

X
X
X
X
X

X
X

X

X
X
X

X
X
X

X
X
X

It is important to have a large enough inlet diameter to allow for ample flow of
blood through the conduit. It is helpful to imagine the system in terms of an electrical
circuit to better understand the important factors in this analysis (Figure 8). In aortic
stenosis, the resistance of the aortic valve is greatly increased and in response the flow
rate decreases and AV pressure gradient increases. The AVB system creates another
parallel path in the circuit. The total resistance of the aortic valve with the conduit is
much less than the resistance of the stenotic aortic valve. The goal of the AVB system is
to return the total resistance to normal levels so that the pressures and flow rates can
return to normal physiologic conditions.
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FIGURE 8 – AVB system shown as an electrical circuit. Left – the left ventricle is
represented as the voltage source with the aortic valve and AVB conduit being
represented with a switch and resistance (Rav and RAVB). The basic relationships between
the systems are shown in upper right table. The total resistance of Rav and RAVB in
parallel in the aortic valve bypass model is much less than the resistance in the aortic
stenosis model.

It is also important to find the point of highest resistance in the AVB system, as
this will ultimately be the critical design feature of the device. In this case, the point of
highest resistance may lie at the narrowest portion of the conduit, which in the current
system is the cannula inserted into the left ventricle. The cannula is the narrowest point in
the AVB system because it offers the most benefits in terms of decreased surgical risk.
As such, the diameter should be as small as possible while still delivering enough blood
to decrease the total resistance back to near normal values.
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Preliminary Cannula Prototype
A preliminary prototype was fabricated and tested for feasibility of concept. A
mock circulation flow loop model was used to investigate the efficacy of the AVB
design. Observations and data from these experiments were instrumental in the creation
of a final, proposed design. The inflow cannula was constructed of Pyrolytic Carbon
(PYC) and measured 7cm in length with 10 mm outer diameter at the cannula interface
that tapers to 7 mm outer diameter at the tip. The prototype was based in part on designs
used in pediatric cardiopulmonary bypass venous cannula and was modeled with the use
of CAD modeling (AutoCad 2006). Figure 9 shows the preliminary prototype CAD
drawings, 3D model, and pictures of the fabricated cannula. The cannula has an open tip
design with 12 side holes to allow for rapid flow of blood from the left ventricle into the
descending aorta.
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FIGURE 9 - Schematics, 3D models, and picture of preliminary prototype fabricated. A)
Drawing of model showing dimensions and sectioned view of the cannula, B) 3D model
of design (AutoCAD 2006). C) Fabricated cannula fabricated of pyrolytic carbon using a
proprietary method (ATS Medical).

Fabrication
The fabrication utilized a proprietary rapid-prototyping manufacturing process
(ATS Medical; Minneapolis, MN). The fabrication process creates a strong, brittle
ceramic design with a high modulus of elasticity. It has been shown that thermal
treatment of pyrolytic carbon at temperatures above 3000°C results in the formation of
blocks having a mosaic sub-structure, which cause a reduction in the azimuthal
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disorientation of carbon produced at a temperature higher than 2000°C in a vacuum,
corresponding to the structure of amorphized natural carbon.

Pyrolytic Carbon
Biocompatibility of implanted materials has been a concern for clinicians due to
the many possible complications, including infection and rejection from the body.
Pyrolytic Carbon (PYC) has been one of the most successful implantable biomaterials,
having been utilized in millions of medical devices worldwide. In other medical
applications, such as heart valves and orthopedic joints, PYC has high durability,
strength, and resistance to wear, while also exhibiting excellent biocompatibility and
thromboresistance. Today, PYC remains the most popular material available for artificial
mechanical heart valves, being used to produce over 4 million devices of 25 different
designs.
PYC was chosen as the fabrication material for the cannula due to these
biocompatibility properties. Slaughter et al. have presented experience with a new type of
proprietary surface modification known as “ForcefieldTM” (ATS Medical) (6). Details of
this experiment are given below. This modification was not used in testing the cannula in
this report, though this unique property was a factor in choosing PYC for prototype
fabrication.
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“Forcefield” surface modification
The Forcefield surface alteration uses an electrostatic charge in conjunction with
protein adsorption from blood to create a biocompatible blood interface that resists
platelet adhesion. A small charge is applied to the experimental PYC over a short
duration in a proprietary process (ATS Medical). A section of PYC with the applied
‘forcefield’ was tested clinically in a cardiopulmonary bypass circuit (CPB) circuit in six
patients and showed a significant reduction in platelet adhesion and activation under
scanning electromicroscopy (SEM) as seen in Figure 10.
Patients undergoing a coronary artery bypass graph (CABG) operation are
exposed to both a control and ‘Forcefield’ modified PYC sample in an experimental
section of the CPB tubing used in perfusion during cardioplegia. The results obtained
from that study show the potential for an increase in biocompatibility, as well as
improvement in thromboresistance for PYC. (6)
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FIGURE 10 - SEM photos of platelet aggregation on “Forcefield” modified PYC and
control PYC samples. The top images show clear platelet activation and spreading across
the PYC while the bottom images show non-activated (round, non-attached) platelets.
The ‘Forcefield’ technology is an important tool used to increase the biocompatibility of
the cannula.

The mechanism(s) behind the non-activation of the platelets on the PYC is still an
area of debate among researchers. This unique property of PYC is still not fully
understood and warrants further study. For the purposes of this report this ‘forcefield’
surface modification was not used as it is outside the main design features being studied.
However, this technology appears promising and will be incorporated into future
experiments.
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‘Seldinger’ Insertion Technique
The current AVB technique commonly uses a 20mm diameter conduit that is
secured through an apical connector during bypass, or more commonly during an off
bypass technique as described previously. One of the main drawbacks is the coring of the
apex and use of a balloon pump to make a large enough opening to allow for suturing of
the apical connector. Often this adds surgical time and risk. To overcome these obstacles,
a Seldinger-like insertion technique is proposed for use with the cannula. The smaller size
of the cannula allows for this type of surgical implantation.
The Seldinger technique is a medical procedure to obtain safe access to blood
vessels and other hollow organs. It is named after Dr. Sven-Ivar Seldinger, who
pioneered the procedure in 1953 (26). It is mainly a technique used for angioplasty,
though the same principles will be used in the insertion of the cannula. The implantation
will employ a small incision at the apex of the heart followed by introducers and dilators
to make an opening large enough for the cannula. The cannula is then secured through
use of a locking ring mechanism sutured on the heart. The main advantage of this type of
technique is avoidance of coring the heart and makes rapid implantation possible. Further
development of the technique and implantation tools will need to be completed in future
work.

29

FIGURE 11 - Inflow cannula (A) designed to simplify and shorten the ventricular apical
implantation procedure by using the Seldinger technique at the apex of the left ventricle
(B). The conduit is then attached to the descending aorta (C). This approach eliminates
the need for placing the patient on cardiopulmonary bypass, avoids ventricular coring,
and achieves hemostasis through a small apical sewing ring and locking mechanism.

Figure 11 shows early, non-published work, of an implantation feasibility study
by Slaughter et al. in a bovine model using the preliminary cannula prototype. This
implantation uses a stab incision with rapid insertion of the cannula into the ventricle.
This work showed that this type of implantation is very promising as there was minimal
bleeding and complications seen at the insertion site. The cannulation system simplifies
the surgical procedure and potentially minimizes morbidity/mortality to promote faster
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recovery. Anticipated benefits of this approach may include rapid application of therapy
with reduced operative time and shorter hospital length of stay.

V. EXPERIMENTAL DESIGN AND METHODS

Three mock flow circulation and CFD analysis was performed on a series of
cannulas to investigate the flow properties. The mock flow loops were a Static Flow
Loop, Dynamic Flow Loop, and a Blood Trauma Loop.

Static Flow Loop
The static flow mock flow loop was utilized to determine the flow versus pressure
drop relationship for different size cannula under constant conditions. Seven different
return venous cannulas were tested for flow characteristics using two variables, type and
size of the tip. The cannulas were obtained from expired or surplus cardiopulmonary
bypass equipment from surplus supplies at the Cardiovascular Innovation Institute. The
aim of this experiment was to hold as many of the variables constant (pressure drop,
velocity) as possible so that differences can be inferred between the cannula types. The
experimental system is shown in Figure 12 and is composed of:
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FIGURE 12 – Static Loop used for analysis of flows for different sized cannula under
static and continuous pressure drop conditions composed of: A) Reservoir, B) Flow Loop
C) DAQ system D) HeartMate II VAD system monitor.

While holding the pressure drop at a constant value, the flow rate was measured.
Figure 13 shows the flow path of the static loop. Plasma-Lyte (Baxter Laboratories) was
used for fluid flow in the static loop. Plasma-Lyte has the same viscosity as water and is a
closer substitute to actual blood plasma than pure water. The tubing was standard 3/8 x
3/32 class VI CPB tubing commonly used in open heart procedures (COBE
Cardiovascular, Inc. Arvada, Co). The test section was composed of a small section of
clear silicone tubing with an injection port for the inlet pressure catheter upstream from
the test cannula.
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FIGURE 13 – Static Flow loop. The white arrows show the path of the flow from the
reservoir to the HeartMate II through the test section and finally out back to the reservoir.
High fidelity Millar catheters were used to measure the Pre-VAD, Inlet and Outlet
pressure. A Transonic flow probe was used to measure the flow rate. A calibration
chamber was used to take pre and post calibration measurements.

The test catheter was inserted into the test section of the static loop so that the
head of the cannula was completely surrounded by fluid as shown in Figure 13 (bottom,
right). 150mL was chosen for the volume of the test section as this is the approximate
volume of the left ventricle at the end of the systolic period and is when the cannula will
experience the highest flow rates.
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The pressure drop across the cannula was created by a small rotary pump, the
HeartMate II (HMII) ventricular assist device. The only controlled variable of the
experiment was the pump speed (revolutions per minute, rpm) of the HMII. In this way,
the pressure drop was controlled and the flow rates for the cannula were directly
compared. The pressure drop was defined as the difference between the inlet and outlet
pressures measured by high-fidelity pressure catheters (Millar Instruments, Houston,
TX), while the flow rate was determined by a transit-time flow probe (Transonics, Ithica,
NY) at the distal end of the cannula.
Each cannula was tested over the HMII operating range of 6,000 to 15,000 rpm
with pressure and flow measurements recorded at 200 rpm increments. Five second
epoch data files were collected utilizing the DAQ system at every 1,000 rpm for postprocessing and analysis. Data was collected once the static loop had reached a constant
value for flow after an increment change. The return reservoir bucket was kept at the
same height and the tubing components were confined to the same path for each run.
After each cannula was tested the loop was filled with Plasma-Lyte back to the same
volume (2,000 ml). Data was then analyzed and plotted with MATLAB and EXCEL
software packages.
The resistance was obtained through a simple regression analysis. The slope of a
linear model can be used as a close approximation of the true resistance. The R-Squared
value was used to determine the accuracy of the resistance. This value ranges from 0 to 1
where a value of 1 represents a perfect fit. This is calculated using the following equation
where SSerr = sum of squares of the residuals and SStot = the total sum of squares value.
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The cannulas ranged from 9.3 - 12mm in outer diameter (28 Fr to 36 Fr) and were
arranged into three groups based on the design features of the tip at the end of the
cannula. Table IV provides the measurements taken from each cannula as well as the
manufacturer of each. The surface area of the opening was approximated and measured
using calipers. The cross sectional area was calculated by measurement of the inner
radius of the cannula. Figure 14 shows the three types of tips that were classified based
from the distinguishing characteristics as Cage, Open, or Dome.

TABLE IV
CHARACTERISTICS OF CANNULA TESTED

Type
Cage
Open
Dome
Open
Cage
Dome
Cage

Outer
Inner
Cross Sectional Surface Area of
Diameter Size Diameter
Area (CSA)
Openings (SA)
Manufacturer
mm, (Fr)
mm
mm^2
mm^2
9.3 (28)
6.5
33.2
47.4
Sarns
9.3 (28)
6.7
35.3
42.0
Research Medical Inc
10 (30)
7.4
43.0
111.0
Terumo
10 (30)
7.5
44.2
153.5
Medtronic
10.7 (32)
7.5
44.2
69.5
Sarns
11.3 (34)
8.8
60.8
144.9
Sarns
12 (36)
8.8
60.8
74.0
Sarns
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FIGURE 14 – The seven cannula used separated by type and size of tip. The Cage type is
distinguished by 4 main holes at the tip formed resembling a cage. The Open type
features an open orifice at the tip with eight sideholes arranged on the head of the
cannula. The Dome type features a smooth dome tip with eight sideholes arranged around
the head of the cannula.

Blood Trauma Loop
To test for possible trauma and damage to blood cells caused by high shear rates
in the cannula, a static flow test using bovine blood was used. The preliminary prototype
cannula was tested in a mock loop with a continuous flow pump (HeartMate II). The
circuit consisted of a 500 ml reservoir, 23cm of standard PVC uncoated tubing, 40
micron inline filter, transonic flow probes and pressure transducers as seen in Figure 15.
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FIGURE 15 – Flow loop used in blood trauma data. A) 500mL reservoir, B) Testing
section, C) HeartMate II continuous flow VAD.

Fresh whole bovine animal blood was collected and stored for less than 48 hours
for performance testing. To minimize the effects of blood variation for tests run with the
cannula, a sufficient amount of blood (5-6 liters) was drawn from a single animal to
permit testing. Blood hemolysis testing followed ASTM international standard F1830
(27). Data collection consisted of blood hematology: white blood cell, red blood cell,
platelet, hemoglobin, hematocrit, and plasma free hemoglobin (WBC, RBC, PLT, HgB,
HCT, PF-HgB). Pump performance (rpm’s and flow rates) and mock circuit status
(pressure inlet/outlet, delta and measured flow rates) were also taken.
The testing conditions were held for at a constant range with the pump operating
at 8400 rpm for the length of the experiment. These test conditions created a pressure
drop of 40mmHg with a constant flow rate of 2.4 lpm. Baseline readings were recorded
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and samples were taken at intervals of 90 minutes for a total of 6 hours. Pressure and
flow measurements were taken from the pressure catheters and Transonic flow probes in
the flow loop. Complete blood chemistry profiles and blood gases were measured with
Gem 4000 (Instrumentation Laboratory, Warrington, UK). Cell counts were measured
with HemaVet 950FS (Drew Scientific, Inc., Dallas, TX). Plasma free hemoglobin was
measured using a HemoCue Plasma/Low Hb Photometer (HemoCue, Inc., Lake Forest,
CA) shown in Figure 16.

FIGURE 16 – HemoCue Plama/Low Hb Photometer used in the trauma study to measure
plasma free hemoglobin.

In compliance with clinical guidelines for VADs (FDA and ISO 7199), blood was
anticoagulated with heparin (4500 units per liter of blood) (28). A minimum Activated
Clotting Time (ACT) of 300s was maintained with additional heparin as needed. To
simulate dilution during bypass, the blood was diluted with normal saline to a hematocrit
of 25 ± 3% for the testing.
Figure 17, Left shows the in vitro flow loop used for the preliminary prototype;
on the Right, the preliminary prototype is inserted into a small silicone o-ring that models
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the Seldinger implantation technique that uses a stab wound to introduce the cannula into
the apex of the left ventricle. Similar to the static flow mock loop experiment, this study
used the HeartMate II continuous flow VAD, in this case set at a constant speed of 8400
rpm.

FIGURE 17 – LEFT: Bovine blood flowing through a mock flow loop consisting of A)
500mL Reservior, B) Standard 23cm CPB tubing, C) HeartMate II Controller, D)
HeartMate II continuous flow VAD, E) Transonic Flow Probe and Pressure Catheter
inside injection port. RIGHT: Preliminary Prototype inserted inside the tubing simulating
the insertion technique used for implantation.
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The flow rate was kept at a constant 2.4 lpm over the course of the 6 hour study.
Heparin was administered throughout the course of the study to maintain a constant ACT
greater than 300 seconds. Also blood samples were taken from the circuit every 90
minutes for blood analysis and heparin was added throughout the study period which has
a slight dilution effect.

Dynamic Flow Loop
The dynamic flow loop study was used to investigate the flow characteristics of
different size cannula under simulated physiologic pressure and flow conditions. A mock
flow loop of the adult systemic circulation was used to test the AVB system. Three
cannula were tested: 1) Prototype design, 2) 32Fr Sarns Venous Return cannula, and 3)
36Fr Sarns Venous Return cannula. The tip design of the three cannulas are very similar
(open distal orifice with sideholes along body of the tip) so the effect of cannula size on
physiologic conditions was the goal of this study.
The test conditions included a baseline with the AVB system clamped off from
the loop, the AVB system under normal physiologic conditions, and the AVB system
under three different aortic stenotic conditions (mild, moderate, and severe). High fidelity
pressure catheters (Millar Instruments, Houston, TX) and transit-time flow probes
(Transonics, Ithica, NY) were used measure simulated cardiovascular pressures and
flows. For each test condition, 15 second data files were recorded using the DAQ
system.
Each cannula was inserted into the apical cannulation port at the apex of the mock
ventricle. The cannula was connected to a 19mm graft and mechanical valve conduit,
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which was connected to a T-junction on the mock descending aorta that completed the
AVB circuit. Glycerol was used for a blood analog with a viscosity of 3.7 centipoise,
similar to that of blood. The flow loop was instrumented to record the following
hemodynamic parameters:







Aortic Flow (AoF)
Aortic Pressure (AoP)
Left Ventricular Pressure (LVP)
Left Atrial Pressure (LAP)
AVB conduit Flow (GRF)
Pressure inside the AVB conduit (GRP)
Aortic stenosis was simulated in the mock loop by applying a clamp to the mock

aortic root. Baseline data was taken where the AVB conduit was clamped off from the
mock loop at the apex and the descending aorta. With the AVB conduit unclamped, four
different AVB configurations were tested: 1) No aortic stenosis under normal
physiological conditions, 2) Mild aortic stenosis, 3) Moderate aortic stenosis, 4) Severe
aortic stenosis. The peak-to-peak pressure difference (peak LVP – peak AoP) was used to
quantify the pressure drop across the valve and assign the degree of aortic stenosis. Table
IV provides the testing conditions used for this study (Table V, Left) and the
transvalvular pressure differences used to simulate aortic stenosis (Table V, Right) as
outlined ACC/AHA Practice Guidelines.
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TABLE V
TESTING CONDITIONS FOR THE DYNAMIC FLOW STUDY.

The experiments were completed at the Cardiovascular Innovation Institute. The
mock loop was tuned to the testing parameters through adjustment of the vascular
resistance and compliance. The degree of aortic stenosis was controlled through
adjustment of a resistance clamp at the aortic root. After the loop had reached a stable
condition, a 15 second data file was taken on the DAQ system. The testing protocol for
cannulas tested was as follows.
1. A baseline reading was taken with the AVB circuit clamped off from the mock
loop, which had been tuned to the testing conditions listed in Table V.
2. The resistance clamp at the aortic root was adjusted until the transvalvular
pressure difference matched the desired value (none, mild, moderate, or severe)
and a baseline reading was taken.
3. The AVB circuit was unclamped and a data file was taken after the system had
reached stability.
4. Steps 2 and 3 were repeated until all four of the AVB configurations were
completed
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5. The aortic root was then fully occluded with all flow going through the AVB
conduit and a data file was taken.
6. A post calibration file was taken with a static circuit where the pump was turned
off and all clamps removed.
7. The cannula was removed from the circuit and the next cannula was placed in the
circuit for testing.

Table VI provides the size of the cannulas, valve, and graph used as well as
photos of the tips of the cannula. The venous cannula used had ‘open’ tip shape with an
open orifice at the distal tip and eight sideholes along the body of the tip.

TABLE VI
CANNULA CHARACTERISTICS
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The data files from the study were first analyzed in using the HEART program
using MATLAB. Each file was picked on a beat-to-beat basis and systolic pressure peaks
were chosen from the plots. Mean aortic flow, distal aortic flow, conduit flow, aortic
pressure, conduit pressure, left ventricular pressure, and left atrial pressure (AoF, AoFd,
GRF, AoP, GRP, LVP, LAP; respectfully) values were calculated. The valve gradient
was calculated from the peak AoP and LVP pressures. Total % Conduit flow was
calculated using the AoF, Aofd, and GRF. Appendix II provides the data obtained and
two sample plots that were beat picked. A total of 37 data files were collected.

Computation Flow Dynamic (CFD) Analysis
Computational flow analysis was used to investigate the effects of design features
of the cannula tip, specifically the number and size of the sideholes on the cannula. The
wall shear stresses, shear strain rate, and flow rate were calculated through simulation in
the ANSYS CFD (ANSYS Inc., Canonsburg, PA, U.S.A.) software package. Differences
in these parameters between cannula designs were used to evaluate flow characteristics.
The CFD analysis was broken into two main studies: Number of Sideholes and Size of
Sideholes.
The CAD models were created using SolidWorks (SolidWorks SP3.0, Dassault
Systèmes; Vélizy, France) CAD software and are similar in design to the preliminary
prototype. A larger view of a typical CAD model for both the cannula and the mesh
model can be seen in Appendix III. The cannulas created for the CFD analysis were all
12mm in diameter and identical to each other with the exception of the number and size
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of the sideholes. Through this method, the characteristics of the sideholes design could be
directly studied.
The CAD files of the cannula designs were loaded into ANSYS workbench
project and the 3D models were checked for continuity. The model was then meshed
using the AutoMesh function (Figure 18) with the appropriate settings for fluid flow. A
fine relevance center sizing was used to ensure ample node and element creation around
those parts of the geometry which have finer detail. The meshes were visually verified for
the proper geometry. Mesh statistics for each cannula are presented in Tables VIII and IX
in the following sections.

FIGURE 18 – The meshing program for ANSYS CFD software analysis. A medium
density mesh was chosen for this analysis.
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Pre-solver software was used to define boundary regions and initial conditions.
Figure 19 shows the defining of the boundary regions and is used to set up the running
parameters. A cylinder (radius = 15mm, length = 50mm) was placed around the cannula
body was used for the inlet boundary region. This allows for development of flow into
the cannula and will allow for more accurate streamlines and vector fields around the
cannula orifices.
The cylinder is placed only around the areas of the cannula that will be inside the
left ventricle and models in vivo-like conditions. The inlet boundary allows for flow to
originate from all sides of the cannula. In this way the wall shear stress and strain can be
measured for all blood contacting portions of the cannula.

FIGURE 19 – Defining the boundary regions and initial conditions for the cannula in the
Pre-solver component software.
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Simulation operating conditions are presented in Table VII. A constant pressure
boundary condition with a pressure difference between inlet and outlet of 6 mmHg was
assumed. The operating fluid, blood, was assumed to be a Newtonian fluid with a density
of ρ = 1.1 g/cm3 and viscosity ν = 0.035 Poise. Flow was not assumed to be laminar as a
k-ε turbulence model was used.

TABLE VII
SIMULATION OPERATING CONDITIONS
CFD Simulation Conditions
Fluid Type
Density
Viscosity

Newtonian
1.1 g/cm^3
0.035 P

Turbulence Model
Boundary Condition
Pressure Gradient

k epsilon
Constant Pressure
6 mmHg

The constant 6mmHg pressure boundary represents the peak systolic transconduit pressure gradient and is based from clinical hemodynamic data (29). Vliek et al.
reported hemodynamic data for AVB intraoperative surgery with a median peak gradient
between the left ventricle and distal conduit in 18 patients (2 with 16-mm apical
connectors, 6 with 14-mm apical connectors, and 12 patients with 12-mm apical
connectors) as measured directly in the operating room of 5.6 +/- 3.8 mmHg (range, 0 to
14 mmHg).
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Examination of the Reynolds number is an important factor in CFD analysis and
was measured at the cannula outlet. This is a dimensionless number that gives a measure
of the ratio of inertial forces to viscous forces defined as Re = U * D/ν (where U is the
average velocity through the orifice, D is the orifice diameter, and ν is the average
kinematic viscosity of blood). Application of this number though is also dependent on the
type of opening. Threshold Reynolds number for turbulent flow is markedly lower
(approximately 800) for flow through an orifice, whereas it is higher (around 3,000) for a
pipe (in this case, a conduit).
The CFX solver ran until the solving equations converged to a final solution. The
post-solver component was then used to analyze and visualize the results. Stream lines,
gradient profiles, vector fields, and slice planes were used for visual analysis while
average, peak, and minimum values for various parameters such as flow rate, pressure,
shear rate, and velocity at the boundary regions were calculated. A custom results report
was generated to obtain desired statistics, figures, and data from the simulations. An
example of the one of these reports can be seen in Appendix IV.

Number of Sideholes Study
This study compared four different 12mm diameter (36Fr) cannulas for
differences in flow characteristics based on the number of sideholes on the tip of the
cannula. This group was comprised of cannula with: No sideholes, 4 sideholes, 8
sideholes, and 12 sideholes. Figure 20 gives the CAD models of each of the four models
as well as the model used for meshing and CFD analysis. The cannulas were identical to
each other with only differences being in the number of sideholes each one featured.

48

FIGURE 20 – The CAD models for the number of sideholes CFD study. Both the
cannula design (left) and the model used for meshing and CFD analysis (right) are shown
for the four different models.

The sideholes on all the cannula in this study were the same size, having an oval
shape with a radius of 3mm and an area of 46.6mm2. This shape and size was chosen as it
is similar to sidehole designs used in the cannulas studied in the mock flow loop
experiments. Table VIII provides the mesh characteristics, surface area, and volume for
each cannula.
TABLE VIII
MESH CHARACTERISTICS.
Number of Sideholes

Nodes
Elements
Area (m^2)
Volume (m^3)

None

Four

Eight

Twelve

68346
370144
3.34E-03
3.65E-05

149169
814855
3.21E-03
3.67E-05

226986
1241999
3.08E-03
3.68E-05

297412
1629111
2.95E-03
3.70E-05
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Size of Sidehole Study
Similar to the number study, the objective of the size study was to determine
differences between 12mm diameter (36Fr) cannula that have different sized sideholes.
Four cannulas with eight sideholes of varying sizes were tested. Figure 21 shows the
cannulas tested which featured small, medium, and large sideholes of the same shape. A
fourth cannula featured the same size sideholes as the medium cannula but did not have
the 0.5mm fillet used on all the edges of the openings. This cannula was used to compare
the effect that fillet geometry had on flow.

FIGURE 21 – The CAD models for the size of sideholes CFD study. Both the cannula
design (left) and the model used for meshing and CFD analysis (right) are shown for the
four different models.

The medium size cannula features the same size sideholes that were tested in the
number of sideholes study. The large size cannula had sideholes that were twice the area
of the medium, while the small cannula had sideholes that were half the area of the
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medium cannula. This provided a nice range of sizes for comparison purposes. The sizes
of the sideholes are presented in Table IX. The radius of the oval shape and total area are
given, as well as the mesh characteristics, surface area, and volume for each cannula.

TABLE IX
AREA OF SIDEHOLES AND MESH CHARACTERISTICS

Size of Sideholes

Radius (mm)
Sidehole Area (mm^2)
Nodes
Elements
Area (m^2)
Volume (m^3)

Small

Medium

Large

No Fillet

1.92
23.13

3
46.26

4.56
92.52

3
46.26

200796
1095191
3.24E-03
3.67E-05

226986
1241999
3.08E-03
3.68E-05

257983
1417062
2.80E-03
3.70E-05

82636
448047
3.17E-03
3.68E-05

VI. INSTRUMENTATION AND EQUIPMENT

Experiments were performed at Cardiovascular Innovation Institute on the
University of Louisville medical campus in Louisville, KY and the Biologic Resources
Laboratory at the University of Illinois at Chicago. Experiments were carried out with the
assistance of Cary Woolard and Michael Sobieski under the supervision of Dr. Steven
Koenig and Dr. Guruprasad Giridharan. The following equipment and materials was
used in the design, testing, and analysis of the cannula:
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Data Acquisition System
o Measurement Instrumentation
 Millar high fidelity pressure catheter
 Transonic Flow probes
o Instrumentation Rack
o Data Acquisition Software
 LabVIEW (National Instruments, Austin, TX)
Mock Flow Apparatus
o Continuous Flow
 Static Flow Loop
 Blood Trauma Study
o Dynamic Flow
 Adult Circulation Mock Flow Loop
Computer Software Packages
o Data Analysis
 MATLAB (The MathWorks, Inc., Natick, MA)
 Microsoft Excel
o Computer Aided Design (CAD)
 SolidWorks (SP3.0 2009, Dassault Systems)
 AutoCAD (AutoCAD 2008, San Rafael, CA)
o Computational Fluid Dynamic (CFD)
 ANSYS CFX (ANSYS Inc., Canonsburg, PA, U.S.A.)

Data Acquisition System (DAQ)
Pressure catheters, flow probes, and the DAQ system was used to measure,
visualize, and store data collected from mock flow loop experiments completed. The
DAQ system was used for all experiments to test the design of both the initial and final
prototypes.

Measurement Instrumentation
Two different types of pressure catheters and flow probes were used in the flow
experiments performed. A high fidelity, dual pressure–volume conductance catheter
Millar Instruments, Houston, TX) was used for simultaneous mock ventricular pressure,
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ventricular volume, and aortic pressure measurements in the dynamic loop. Single tip,
high fidelity catheters (Millar Instruments, Houston, TX) were inserted into introducer
ports for measuring pressures in both static and dynamic flow loops. Flow was measured
with clamp and in-line, transit time flow probes (Transonics, Ithaca, NY) were also used
in both experiments. Pressure and flow transducers were calibrated before and after to
verify gain and offset accuracy.

Instrumentation Rack
The instrumentation rack was composed of transducers, amplifiers, and signal
processors. This custom built clinically approved Good Laboratory Practices (GLP)
compliant DAQ rack is described in Koenig et al. (30) and was used to collect and store
data from the mock loop studies shown in Figure 22. Signal conditioning was completed
using transducer amplifiers (Ectron, San Diego, CA), a transit time flowmeter
(Transonics, Ithaca, NY), a volume conductance unit (Leycom, Sigma V, Netherlands),
and other peripheral conditioners integrated into the instrumentation system. Signal
conditioned data were low pass filtered at 60 Hz, analog to digitally converted (AT-MIO16E-10 and LabVIEW, National Instruments, Austin, TX) at a sampling rate of 400 Hz,
and stored on a personal computer (7).
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FIGURE 22 – DAQ system used to collect and store data from the mock flow loop
studies used to characterize the cannula (30).

This DAQ system allows the user to connect a variety of instrumentation and then
condition, amplify, and process the signals. A 16-channel signal conditioning and
distribution unit is used to drive multiple peripheral monitoring and recording devices.
The DAQ system has fixed gain and offset control to maximize A/D input range of
peripheral devices, and low-pass filters to remove electrical noise and prevent aliasing.
An analog to digital converter then allows for data storage. Signals from pressure
catheters and flow probes are amplified and conditioned and are seen real-time on the
monitor. Further detail concerning the components, construction, and operation of the
DAQ unit is outlined in Koenig et al. (30).
The software used to for data acquisition is also a custom built LabVIEW
(National Instruments, Austin, TX) described by Drew et al. (31,32). This graphical

54

oriented program gives users a plethora of tools to aide in the capture and analysis of
data. The Cardiovascular Data Acquistion Software (CDAS) program developed by this
group allows for custom setup for the 16 channel DAQ system. After the user has set up
the desired profile, the program is run and allows for real-time display of waveforms
collected from experiments. Figure 23 shows a layout of real-time waveform collection
and GUI.

Overlay Select

Subject
Name/Number
Next Data Set
Sequence
Number

Channel Name

Mean Value

Exit Graphs and
Return to Program
Menu

Freeze Select

nd

Continuous
Data Save

Data Set Notes
and Comments

When selected, 2 subject control
Mean Pressure
and Flow
Display Select

Epoch Data Set Save

FIGURE 23 – The DAQ system allows for real-time monitoring and collection of data
from waveforms produced from pressure and flow transducers (30).
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Adult Circulatory Mock Flow Loop
In order to study the flow characteristics of the cannula under physiological like
conditions, an adult mock circulatory flow loop was utilized. Investigators at the
Cardiovascular Innovation Institute have developed the mock loop mainly for testing of
cardiac devices in normal and pathologic states (7). Pantalos et al. describe the in vitro
circulatory system, which can produce physiologically equivalent pressures, volumes,
flows as to faithfully reproduce normal, heart failure, and partial cardiac recovery
physiologic states as a platform for testing platform for testing cardiac devices (7).This
mock loop circuit was used to complete in vitro dynamic flow testing on the cannula
(Figure 24).

FIGURE 24 - Adult circulation mock flow loop developed by Pantalos et al (7).
Physiologically equivalent pressures, volumes, flows are used to reproduce normal, heart
failure, and partial cardiac recovery physiologic states of the heart.
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The adult mock flow loop consists of a mock ventricle with atrial and apical
inflow cannulation sites, mock systemic vasculature with aortic root and descending
thoracic aorta outflow cannulation sites, and mock coronary vasculature. The mock
ventricle is powered and controlled by a pneumatic driver. Figure 25 gives a diagram of
the mock loop. This mock loop is able to faithfully produce the Frank–Starling response
with physiologic characteristic hemodynamic parameters and pressure–volume
relationships under a variety of testing conditions. The cardiac and vascular
hemodynamic waveforms of the mock circulation are comparable to natural physiology
in both magnitudes and morphologic features.

FIGURE 25 – Diagram of the adult circulation mock flow loop developed by
Pantalos et al (7). Due to its versatility and robustness, the mock loop is able to test the
AVB system providing a powerful in vitro testing environment.
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The versatility of this system allowed the entire aortic valve bypass system to be
tested. The cannula was introduced to the apical cannulation site of the mock ventricle
and was connected to a conduit and valve eventually connecting to a T-junction in the
mock descending aorta. This setup allows for in vitro testing of the AVB system as a
whole and provides conditions very similar to what the cannula would experience
clinically. Using the pressure and flow instrumentation previously described, the mock
loop was instrumented to measure: Aortic Flow (AoF), Aortic Pressure (AoP), Left
Ventricular Pressure (LVP), Left Atrial Pressure (LAP), Flow though the AVB conduit
(GRF), and Pressure inside the AVB conduit (GRP).
Choice of fluid was also important in creating near physiologic testing conditions.
Glycerol was used as a blood analog in the flow loop. The viscosity of the glycerol used
in the loop was 3.7 centipoise, which is very similar to blood. Investigators have shown
that this material provides a good blood analog fluid for flow conditions characteristic of
large arteries. Because the fluid is transparent and made from readily available and fairly
inexpensive materials, it may be generally useful for in vitro hemodynamic studies,
particularly those employing optical techniques (33).

Computer Software Package
A host of computer software programs were used in the design and analysis of the
cannula. AutoCAD (AutoCAD 2008, San Rafael, CA) was used to create the initial
model while SolidWorks (SP3.0 2009, Dassault Systems) was used to create the final
cannula and AVB system model. The schematics and CAD data files were sent to ATS
Medical for fabrication. Primary analysis of data collected from mock loop experiments
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and CFD computations was completed using the MATLAB (MathWorks, Inc., Natick,
MA) software package.
Characterizing hemodynamic parameter values were calculated using the custom
MATLAB program HEART (Hemodynamic Evaluation and Assessment Research Tool)
developed by Schroeder et al. (34). All hemodynamic parameters were calculated on a
beat to beat basis and averaged over the entire data set to obtain a mean value for each
parameter. Sample hemodynamic waveforms for each data epoch and test condition were
plotted for post-analysis to validate waveform fidelity. Microsoft Office 2007 software
package (Excel, Word, PowerPoint) was also used for preparation of graphs and tables.
Computation flow analysis was completed with the ANSYS CFD (ANSYS Inc.,
Canonsburg, PA, U.S.A.) software package. The CAD files of the cannula designs were
loaded into ANSYS workbench project and the 3D models were checked for continuity.
The model was then meshed using the AutoMesh function with the appropriate settings
for fluid flow. Pre-solver software was used to define boundary regions and initial
conditions. The CFX solver was then utilized and the computation ran until the solving
equations converged upon a final solution. Post-solver component was then used to
analyze and visualize the results. Stream lines, gradient profiles, vector fields, and slice
planes were used for visual analysis while average, peak, and minimum values for
various parameters such as flow rate, pressure, shear rate, and velocity at the boundary
regions were calculated.
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VII. RESULTS

Static Flow Loop
The data was then plotted with the pressure drop vs. flow rate to determine the
flow characteristics. As discussed previously, the resistance of the cannula can be
measured by taking the change in pressure and dividing by the flow rate.
R = ΔP / Q
The steeper the slope of the pressure drop versus flow rate curve, the higher the overall
resistance is to flow. Figure 26 shows the flow profiles for all cannula tested. The
resistance decreases significantly as the size of the outer diameter is increased.

FIGURE 26 – Flow profiles for all seven cannula tested in the static flow loop and shows
resistance to flow decreases with increasing diameter size. Legend Key: C - cage, O –
open, D – dome. Outer French (Fr) diameter sizes are given.
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Resistance values and the R-Squared value for each cannula are reported in Table
X. The 28Fr (9.3mm diameter) cannulas had the highest resistance values among all the
cannula. The 30Fr cannula had almost half the resistance of the 28Fr cannulas and
resistance decreases slightly as size is increased from this size. The R-squared values are
high with all cannula greater than 0.979 showing good linear approximation fit.

TABLE X
STATIC LOOP RESULTS FOR TESTED CANNULAS
Resistance
(linear regression R-Squared
model)
28-C
20.9
0.984
28-O
21.9
0.982
30-D
13.3
0.981
30-O
10.4
0.982
32-C
13.1
0.979
34-D
9.4
0.979
36-C
7.3
0.979
Legend: C - cage, O – open, D – dome.
Outer French (Fr) diameter sizes are given.
Units of Resistance = (mmHg*min)/L

Blood Trauma
Table XI presents the results from the blood chemistry and plasma free
hemoglobin testing. Over the course of the 6 hour study all the blood chemistry stayed
within normal values for the bovine model. The WBC, RBC, HGB, HCT, and PLT
counts all decreased slightly while the plasma free hemoglobin slightly increases over the
study period though this can be expected as the blood outside the body degrades over
time.
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All plasma free hemoglobin measurements were well under 100 mg/dL indicating
little to no hemolysis. The device, the HemoCue Plasma/Low Hb, used to measure the
plasma free hemoglobin has a linear measuring range between 0.3-30.0 g/L. The device
manufacturer advises caution for evaluating instrument readings below 30mg/dL.

TABLE XI
RESULTS FROM TRAUMA MOCK LOOP TESTING
Time
1030
1200
1330
1500
1625
1635

Condition
Baseline
Sample
Sample
Sample
Sample
Sample

Blood wt.
g
651
-10
-10
-10
-10
-5

Flow
lpm
2.4
2.4
2.4
2.4
2.4
2.4

Pressure Drop
mmHg
40
40
42
41
40
40

ACT
sec
>300
>300
>300
>300
>300
>300

WBC
RBC
thous/uL mill/uL
5.34
6.8
5.46
6.77
5.39
6.77
5.3
6.77
4.93
6.72
4.9
6.7

HGB
%
8.6
8.6
8.6
8.6
8.6
8.6

HCT
%
22.7
22.5
22.5
22.5
22.4
22.4

PLT
thous/ul
889
877
863
851
846
824

The pfHb increased over the experiment to a final reading of 40mg/dL, which is
slightly larger than the minimal detection levels of the HemoCue again showing no
significant levels of hemolysis.

Dynamic Flow Loop
The flow rates for each cannula are presented in Table XII. For severe AS, the
peak flow rate through the preliminary prototype was 0.6L/min, while the 32Fr and 36Fr
provided flow rates of 1.65L/min and 2.55L/min, respectively. With the aortic root fully
clamped off, the maximum flow rates through the prototype cannula was 1.49 L/min,
while the 32Fr and 36Fr had flow rates of 3.31 L/min and 3.87 L/min, respectively.
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pfHb
mg/dL
10
20
20
30
35
40

TABLE XII
PEAK FLOW RATES FOR CANNULA UNDER DYNAMIC TESTING CONDITIONS

Flow (L/min)
Aortic Stenosis Prototype
None
0.34
Mild
0.40
Moderate
0.57
Severe
0.6
Complete
1.49

32Fr

36FR

0.85
1.4
1.65
3.31

1.17
1.15
1.7
2.55
3.87

The AVB system showed a trend of decreased transvalvular pressure difference
for all three cannula under most conditions. Figure 27 shows the baseline valve gradient
with the AVB arm clamped off and the valve gradient when the AVB system is in use.
The largest difference can be seen for the severe arotic stenosis condition although the
preliminary prototype showed no improvement.
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FIGURE 27 – Difference in valve gradient (LVP – AoP) from the adult
circulation mock flow loop between baseline and with the AVB system. Improvement
can be seen as the cannula diameter increases. The largest improvement can be seen in
the 36Fr cannula for the severe aortic stenosis condition.

Figure 28 shows the % conduit flow increases with cannula size. The prototype
again showed poor performance, as only 15% of the fluid flow was through the cannula.
The 32Fr cannula showed an improvement to 36%, while the 36Fr cannula had the best
performance at 59%.
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FIGURE 28 – Relative conduit flow as a percentage of total cardiac output. %
Conduit flow provides a measure of the effectiveness of the cannula in the AVB system.
The percentage increased as cannula size was increased.

Computational Dynamic Flow Analysis
Two studies were performed on a 12mm diameter (36Fr) cannula to see the effect
of number and size of the sideholes on wall shear stress, shear strain rate, and flow
characteristics. For each computational run, a custom report was used to gather the flow
parameters and create figures. A sample report is presented in Appendix IV.

Number of Sideholes Study
The flow rates at the outlet for each cannula are presented in Figure 29. Flow
slightly increased as the number of sideholes increased, although, the cannula with no
sideholes had the highest flow of 4.1 L/min. These values remain very similar to one
another with the largest difference being 0.3 L/min.
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FIGURE 29 – Flow rates for 12mm diameter (36Fr) cannula with different numbers of
sideholes.

Figure 30 presents a cross sectional view of the velocity profiles for all four cases.
The largest velocities are seen in the cannula with no sideholes. In the cannulas with
sideholes, the max velocities occur at the bottom of the most distal sideholes. These high
velocity areas are the same areas that contained the largest shear stress, seen in Figure 31.
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FIGURE 30 – Velocity profiles for the number of sideholes study. Four (Top Left), Eight
(Top Right), Twelve (Bottom Left), and No Sideholes (Bottom Right).
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FIGURE 31 – Shear wall stresses for the number of sideholes study. Four (Top Left),
Eight (Top Right), Twelve (Bottom Left), and No Sideholes (Bottom Right). The highest
wall shear rates are seen on the bottom edges of the most distal sideholes.

Flow rate and Reynolds numbers at the outlet as well as shear wall stress and
strain rate are reported in Table XIII. The reported Reynolds numbers for all cases were
greater than 3000 indicating turbulent flow at the outlet. Shear strain rate decreased as
sideholes are increased. Flow and maximum strain rate both increase with addition of
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sideholes though the No sideholes cannula has the largest values. Maximum shear
stresses increases with addition of sideholes.

TABLE XIII
RESULTS OF NUMBER OF SIDEHOLES STUDY
Number of Sideholes
None

Four

Eight

Twelve

4.1

3.8

3.9

4.0

Reynolds #

3349

3096

3174

3293

Wall Shear Stress (mmHg)
Max Shear Stress

0.124

0.144

0.152

0.165

Shear Strain Rate (s^-1)
Max Shear Rate

258.4
891

187.6
851

141.1
829

118.4
876

Flow (L/min)

Size of Sideholes Study
The flow rates at the outlet for each of the four cannulas are presented in Figure
32. Flow rate increased as size increased. Similar to the other study, the largest
differences in flow between the cannulas was only 0.3 L/min. The cannula with no fillet
had slightly more flow than the medium sideholes but remained less than the large
sideholes.
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FIGURE 32 – Flow rates for cannula in the size of sideholes study. The cannula with no
fillet has the highest flow rates.

The cross sectional velocity profiles are presented in Figure 33. Similar to the
number of sideholes study, the highest velocities are seen on the bottom edges of the
sideholes most distal from the tip. The cannula with small sideholes experienced the
largest wall shear stresses, which decrease with increasing size shown in Figure 34.
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FIGURE 33 – Velocity profiles for the size of sideholes study. Small (Top Left),
Medium (Top Right), Large (Bottom Left), No Fillet (Bottom Right).
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FIGURE 34 – Shear wall stresses for the size of sidehole study. Small (Top Left),
Medium (Top Right), Large (Bottom Left), No Fillet (Bottom Right)

The results of this experiment are presented in Table XIV. Similar to the number
of sideholes study, all cases have turbulent flow. Flow rate, Reynolds number and
maximum shear stress increased with increasing size. The No fillet cannula showed
slightly higher flow, less shear stress and less strain rate than the medium cannula.
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TABLE XIV
RESULTS OF SIZE OF SIDEHOLES STUDY
Size of Sideholes
Small

Medium

Large

No Fillet

3.8

3.9

4.1

4.0

3093

3174

3320

3227

Wall Shear Stress (mmHg)
Max Shear Stress

0.1383

0.152

0.164

0.156

Shear Strain Rate (s^-1)
Max Shear Rate

189.5
1020

141.1
829

109.3
712.3

68.8
651.4

Flow (L/min)
Reynolds #

VIII. DISCUSSION

Static Loop
The results from this experiment provide two insights. First that the resistance to
flow decreases with increasing cannula diameter and second that an “open” tip design,
which is a design that incorporates an orifice at the most distal tip featuring 8 sideholes
arranged in 2 sets of 4 openings, seen in Figure 35, is preferred over other designs
studied. The diameter plays a large role in the resistance while the tip design plays a
much smaller but still important role. These results were used to aid the design
characteristics chosen for the final AVB model.
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FIGURE 35 – ‘Open’ tip design that includes an open orifice with 8 sideholes displayed
the best flow characteristics from the three designs studied in static loop testing.

This data shows the significant differences between the different sized cannula.
The resistance values for the 28Fr cannulas are as high as 21.9 while the 36Fr cannula
remains in single digits at 7.3. The R-Square values that represent the linear
approximation of the resistances are correlated well and show a good fit. It is evident
from the data that there is a sharp difference between the 28F and 30Fr compared to the
other increments. This suggests that the diameter plays a large role in the resistance and
at a critical point between these two sizes. It may be undesirable to have an apical
cannula this small due to the likely drop in flow rates. From this data it is favorable to
select a cannula size of 30Fr (10mm) or larger.
To validate the data obtained, pressure drop vs. flow rate graphs were compared
to ones obtained from the cannula manufacturer (35). The data obtained from the static
loop testing closely matches the pressure/flow plots obtained from the manufacturer, an
example can be seen in Figure 36. The figure shows that the flow rate and pressure drop
values measured (Figure 36– right) are almost identical to the values obtained from the
manufacturer (Figure 36– left).
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FIGURE 36 – Pressure Drop vs. Flow Rate data obtained from the cannula manufacturer
to the left with data obtained from static loop testing on the right. The top figure shows
the ‘open’ tip Sarns Malleable Venous Return Catheters while the bottom shows the
‘cage’ tip Sarns Venous Return Catheters. The data obtained from the manufacturer
closely matched data obtained and validates observations made in the experiment.
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This data from the manufacturer also shows the large differences seen as the
diameter of the cannula is decreased. Specifically, this data also shows that the 28Fr and
smaller cannula show a significantly increased resistance compared to larger cannula.
Also the critical point where the resistance increases dramatically is in the area between
28Fr and 32Fr for all three of the cannula designs. This confirms the observations that the
diameter size plays the most important factor in resistance to flow and the design of the
tip plays a secondary but important role.
Comparing the plots between the three designs, the results show that the open tip
design has lower flow resistance across almost all sizes. It can be inferred that the orifice
at the tip with the addition of sideholes along the body are important features that
contribute to improved flow characteristics.
Explanation of these results can be found in comparison of the features of the
three designs. The cage design is primarily a design where the tip allows flow through
openings at the very distal end and features no sideholes along the body of the tip. The
dome design, in contrast, has no opening at the distal most point and has all of the flow
come through 8 sideholes along the body of the tip. It seems that the open design features
both of these characteristics with an orifice at the distal tip and sideholes along the body
and show superior flow characteristics compared to the dome and cage designs.

Blood Trauma
The results from this experiment indicate that there is minimal to no hemolysis
caused by flow in the preliminary prototype. This study gives confidence for use of the

76

fabrication material (pyrolytic carbon) and the tip design of the cannula (one with an
open orifice at the distal most tip with sideholes along the body of the tip).
The results from this study show minimal to little hemolysis using the preliminary
prototype cannula. The cannula has an outer diameter of 7mm at the distal-most tip and
as such had a higher resistance to flow compared to the cannulas studied in all
experiments performed. The values for all blood chemistry and plasma free hemoglobin
showed little change from baseline to the study endpoint. The size and design of the
cannula did not shear or damage the red blood cells in a significant manner.
The biocompatibility of the pyrolytic carbon was shown to be a good choice as a
fabrication material. The strong track record for use of this material in other medical
devices, most notably mechanical valves, has been well documented and is discussed
previously. The use of the anticoagulation drug, heparin, prevents an analysis on possible
thrombus formation, though the use of CFD can pinpoint possible stagnation points.

Dynamic Flow Loop
The results from the adult mock circulation testing are similar to those obtained in
the static loop testing. The results show that the preliminary prototype is too small to be
clinically effective as a treatment for aortic stenosis. Flow rate and % Total flow through
the conduit increased with increasing cannula size. The results show a trend of
improvement in valve pressure difference between stenotic baseline conditions and the
mock loop circuit with the AVB system. These results aid in development of a final
design for the AVB system.
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These results show that the size of the cannula play a critical role in improvement
of aortic stenosis condition. This data also shows substantial improvement only when the
aortic stenosis is severe. There is a significant difference between the prototype and 32Fr
compared to the difference between the 32Fr and 36Fr. These results are similar to the
static flow results where there exists a critcal point between 30Fr and 32Fr (10mm and
10.7mm) in the tip size that critically impedes flow through the cannula.
When studying the % conduit flow, the 36Fr shows improved performance over
the 32Fr and prototype. For comparison, a recent investigator presenting early and
midterm hemodynamics after AVB surgery reported initial relative % conduit flow to be
63%+- 10% for 47 patients who had received AVB surgery (29). These results show that
the 36Fr cannula is the best choice for treatment of severe aortic stenosis of the three
cannulas studied. The size of the 36Fr cannula (12mm) may be the smallest cannula tip
size that will still give significant improvement in the valve gradient for patients with
aortic stenosis.

Computational Flow Dynamics Analysis
The two blood damage phenomena potentially occurring in an in implant of a
blood contacting artificial material are thrombosis and hemolysis. Thrombosis refers to
the formation and growth of blood clots. Hemolysis is hypothesized to be a function of
cellular exposure to high shear stress and the length of time over which this exposure
occurs. The processes that cause thrombosis and hemolysis to occur in complex flow
situations are still not completely understood. The general understanding is that cellular
exposure to high shear stresses can lead to hemolysis (36) and platelet activation (37)
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while regions of low shear stress and/or flow stagnation can be susceptible to thrombus
deposition (38).
Blood is a suspension consisting of primarily red blood cells, along with other
formed elements which contribute to its viscoelastic behavior. Blood behaves as a
Newtonian fluid at shear rates above 500 s-1. At shear rates lower than 50 s-1 the viscosity
of blood increases exponentially, due to the formation of large aggregates of erythrocytes.
The presence of shear and strain stresses are important for the ideal biocompatibility with
the body. The best situation is to have shear stress throughout the flow just high enough
to prevent aggregation and thrombus growth, but not so high as to cause trauma or
platelet activation.
Previous studies done by investigators have found that shear stresses on the order
of 1500-4000 dynes/cm2 can cause hemolysis (39). Sub-lethal damage to red blood cells
can occur at turbulent shear stresses of 500 dynes/cm2 (40). Platelets are more sensitive
and can be damaged by shear stresses ranging from 100-500 dynes/cm2 though this is
also very much dependent on the duration of the applied shear stress (41). The wall shear
stress from the CFD analysis can provide a prediction for hemolysis and platelet
activation. Comparisons between the cannulas can be made to evaluate design choices.

Evaluation of Cannulas
The highest flow rates were seen in the No sideholes cannula and the Large
sideholes cannula with both having 4.1 L/min flow. No sideholes cannula had a lower
max shear stress (0.124 mmHg) than the Large cannula (0.164 mmHg). The Large
cannula has larger areas of lower shear stresses located near the tip. Although it seems a
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little counterintuitive, the cannula with no sideholes showed the best blood
biocompatibility of all the cannulas studied. This does not make this cannula the ideal
choice for this application though as the differences between the cannulas is still only
slight and other factors such as device safety play a role in selection of the best cannula.
The more fully developed flow in the tube with no sideholes has walls that are
washed and the shear stress is safely low giving it better blood compatibility the other
cannulas studied. The sideholes, on the other hand, produce high shear stresses at the
distal end of their openings, and could cause recirculation regions downstream of the
holes that promote thrombus growth and attachment. The increase in number of sideholes
in essence makes the tube shorter, since a majority of the flow is coming in through the
distal holes and very little is coming through the proximal holes.
The shape of the ventricle around the cannula once inserted likely has a great
amount of influence on the direction of flow. The surgical placement of the cannula is
paramount to the performance of the cannula. If the cannula was improperly placed with
one side of the tip lying against a ventricular wall, then full flow will not be achieved. In
terms of safety, the addition of sideholes allows fluid to enter from all directions so flow
rates can be more consistent while the ventricle is pumping. As the No sidehole cannula
has only one inlet, if something were to occur to block or partially occlude the opening
(i.e. cannula is against the ventricular wall) the flow could diminish in the conduit and
may allow stagnation of blood in the entire AVB system.
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Wall Shear Stress
When looking at the wall shear stress, the average may not be a very useful
indicator and can be very misleading.. There is so much surface area at the proximal part
of the tube that has very low wall shear stress that when added to the higher shear stresses
at the distal sideholes, the average shear stresses become diluted. Instead investigation of
max shear stress may be more helpful and the areas that they occur.

FIGURE 37 – Wall shear stress for all cannulas studies. Color above blue represents a
shear stress level that exceeds 0.125 mmHg (166 dynes/cm2). The addition and size of
sideholes increases the areas of high shear stress.
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To directly compare the wall shear stresses and determine the areas of high shear
stress, the scales on the figures were adjusted to highlight areas higher than this threshold.
Figure 37 shows all cannulas studied, the blue area represents any area under a minimum
threshold of 0.124 mmHg (166 dynes/cm2), while any color above it represents areas of
higher stresses. As the number and size of the sideholes increases, the areas of higher
stress increase. The maximum shear stress measured was 0.165 mmHg (220 dynes/cm2),
which is still significantly lower than the threshold for hemolysis of 1500 dynes/cm2.
The levels of shear stress seen in all the cannulas are lower than the critical
amount needed to activate platelets. At 150 dynes/cm2, it takes 300 s for platelet
aggregation to occur (41). The CFD flows are assumed to be during systole, so there is
not enough duration of shear stress to cause activation at the calculated values levels.
Even though there are differences between each design, the levels of wall shear stress
remain with-in safe values for hemolysis and platelet activation for all cannula.
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FIGURE 38 – Wall shear stress for all cannulas studies. Any color below red represents a
shear stress level lower than 0.02 mmHg (27 dynes/cm2). The addition and size of
sideholes increases the areas of low shear stress near the tip and proximal sideholes.

In a similar way, the areas of low shear stress were also compared for the
cannulas studied. Figure 38 shows areas of lower shear stress for colors below the red
threshold of 0.02 mmHg. This figure highlights the increase of lower shear stress areas as
the number and size of the sideholes is increased. As more flow enters the more distal
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sideholes, the proximal sideholes have less shear energy imparted on the wall surface.
These areas could potentially lead to thrombus formation. The fluctuations
between systole and diastole may help prevent thrombus formation. Looking at the
velocity plots, examining the streamlines (Figure 39), and pressure field plots show flow
through the proximal holes.

FIGURE 39 – Streamlines for 12 holes cannula

Likely just as important for this analysis is in the choice of the material used in
fabrication. The nature of thrombus and platelet attachment is still an area of broad
research. In vitro or animal in vivo studies are needed to properly study the effects of
thrombus formation for the cannulas. The use of pyrolytic carbon and the application of
the Forcefield technology described previously could greatly increase the
biocompatibility of the cannula.
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Effect of No Fillet
The fillet used on all the cannulas are part of the fabrication process that smooth’s
out the rough edges created during fabrication. Sharp edges on the cannula can possibly
damage tissue when implanted. These edges are also rounded, as it is believed that the
rounded edges can help direct stream lines of flow into the cannula and reduce the
concentration of high wall shear stress at the distal edges of the sideholes. Figure 40
shows a cross sectional velocity vector field for the medium and no fillet cannulas.

FIGURE 40 – Velocity vector fields on cross section of Medium and No Fillet cannulas.
The No Fillet Cannula had slightly higher flow and similar shear stress properties to the
Medium cannula.

It can be seen in Figure 40 that the flow is indeed directed and shows a more
uniform vector profile than what is seen in the no fillet cannula. The two cannulas are
identical in size and geometry except for the addition of the fillet. Interestingly, the flow
rate and Reynolds number are slightly higher in the no fillet cannula. Maximum shear
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stress and the distribution of high/low areas of stress do not show many differences,
however higher resolution simulation of the flow over the distal edges of the sideholes
may show the expected reduction in wall shear stress concentration produced by rounding
these edges.

Additional Benefits of AVB Technology
Another possible benefit of the AVB system may be a brain protective advantage
over aortic valve repair. Balaras et al have completed a computational model that show
that cerebal blood flow is increased to the aortic head vessels even with small conduits
(10mm). This provides an advantage over typical aortic valve repair as there is a much
higher risk for stroke during operation and postoperatively in AVR for the high risk
patient groups. Figure 41 from their report shows the systolic flows for pre-operative,
20mm conduit, and 10mm conduit.
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FIGURE 41 – Results from Belaras et al. Through computational modeling a brain
protective advantage is presented for AVB over AVR. They also conclude that cannula as
small as 10mm can relieve left ventricular outflow tract obstruction in critical aortic valve
stenosis (42).

The effect of AVB configuration may decrease the long-term risk of cerebral
thromboembolism. The conduit provides a second path that possible clots or emboli can
be shot into the peripheral vasculature instead of ending up in the cerebral vessels. They
report that in all cases modeled, cerebral blood flow remained the same post-operatively
from pre-operative levels (42). The brain was adequately supplied from blood ejected
through the native aortic valve. The study also concluded that cannula as small as 10mm
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in diameter can relieve left ventricular outflow tract obstruction in critical aortic valve
stenosis.

Type of Flow
The flow is split between the native stenotic valve and conduit in an interesting
fashion. Surprisingly the pressure gradients are different for these two paths. The conduit
is characterized by minimal directly measured pressure gradients. Clinically the low
conduit gradient has been confirmed in patients while the pressure gradient for the native
aortic valve remains higher averaging 17 mmHg (29). The difference between these
gradients is almost 4-fold.
The difference implies that the energy loss experienced by the blood element
moving through the stenotic valve is much higher than the one experienced by a blood
element moving through the conduit. Losses in the conduit are primarily due to shear
stresses from the conduit walls and losses from the prosthetic valve as well. In contrast,
losses in the native aortic valve are through kinetic energy as blood decelerates
inefficiently across the valve. These losses are higher than ones due to wall stress and can
be amplified in the case of turbulent, disturbed flows (29).
The difference in mean gradients is consistent with the split of flow between the
two elements. Data from the dynamic flow loop, clinical data, and computational data all
show this spit of approximately 60:40 in relative % flow in the conduit and aortic valve
respectively. The results suggest, as some researchers have described, that the flow split
is determined largely by ventricular systolic geometries and to a small extent by the
gradient across the native aortic valve (29).
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Cannula Size
The largest question in the development of this technology is: what is the smallest
size that can be used to achieve adequate relief? The benefits of decreasing the conduit
sizes are many with the most important being a decrease the intraoperative risk in the
surgical insertion of the conduit. A smaller cannula translates into a smaller stab incision,
less bleeding in left ventricular apex, and less suturing needed to secure the cannula. The
currently used systems commonly use conduits and components that are 20mm in
diameter, though many believe that this size could be much smaller and still obtain
adequate treatment of aortic stenosis. Brown and Gammie state, “Because the conduit is a
second avenue for left ventricular outflow, we believe that a conduit smaller than what
would normally be used for a conventional aortic valve replacement is acceptable and in
most instances desirable” (23).
The tip size was chosen on basis of the experiments run and on clinical data. Most
AVB apical cannulas in the past have been 20mm in diameter. As the technique gains
more usage though, investigators are using smaller and smaller cannula for the procedure
(3). Vliek et al. recently published clinical data on hemodynamics for a number of sizes
of cannulas used that ranged from 20mm to 12mm. They found that cannula size did not
significantly affect % flow in the conduit, but that there was a relationship between
cannula size and valve pressure gradient (29). Figure 42 shows the data from this report,
there is a upward trend in aortic valve gradient as the cannula size decreases (Figure,
Top) while there is no effect on % flow due to cannula size (Figure, Bottom).
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FIGURE 42 – Data from Vliek et al. showing upward trend in valve gradient as the
cannula size decreases (Top) while there is no effect on % flow due to cannula size
(Bottom) (29).

The mock loop studies that were performed in this thesis work, specifically the
results from the preliminary prototype, show that cannula beneath 10mm are not suited
for use in AVB. Belarus et al. presented a computational model where 10mm cannula can
effectively treat aortic stenosis though more favorable flow was seen in larger cannula,
such as those presented in the mock flow loop experiments in this thesis work (42).
Clinical data shows favorable results for cannula that are 12mm in diameter (the smallest
conduits in current use).
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Tip and Sideholes
The design of the tip was based from the results seen from the static loop testing.
The open straight tip will allow for a larger amount of inflow than a tip that narrows to a
smaller opening diameter. The mock loop flow tests show that a design that incorporates
an open orifice at the distal most tip and inclusion of sideholes along the body is the most
desired design. The use of sideholes is to decrease sidewall shear stress and maximum
blood velocities to avoid hemolysis. Park et al. used a computational model to study the
effect of sideholes in venous cannula. They found that flow rates in the cannula are not
proportional to the number or arrangement of sideholes. They concluded though that
larger number of sideholes can reduce the mean shear rate (43).

IX. CONCLUSIONS

Static Loop Testing
In this study, a simple test to look at the most important features in the cannula tip
was completed. Three different designs were investigated, which showed that diameter
plays a large role in the resistance while the tip design plays a much smaller but still
important role. The key findings were: (1) the resistance to flow decreases with
increasing cannula diameter and (2) an “open” tip design, which is a design that
incorporates an orifice at the most distal tip featuring 8 sideholes arranged in 2 sets of 4
openings, is preferred over other designs studied. Also, it demonstrated that diameter
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sizes above 10mm (30Fr) are favored, since smaller cannulas have a much higher
resistance.

Limitations
A relatively small sample size (n=7) and evaluation of only three clinically used
designs were included in the experimental design to demonstrate feasibility of concept.
These designs were selected to highlight important characteristics of the tip design and to
simplify the analysis of these cannula. Knowledge of the manufacturer’s experimental
methods is incomplete (proprietary intellectual property), making comparision of
experimental data a challenge, though the density and viscosity of the Plasma-Lyte
solution used in the current experiment is nearly identical to the water that the
manufacturers used for their in vitro evaluations and should have the same flow
characteristics. Some of the cannulas used for study were expired for medical use, though
the flow characteristics of the cannula should be unaffected, since the expiration date
relates more to the sterility of the cannula than degradation of the materials.

Blood Trauma Testing
No hemolysis, platlet activation, or blood damage observed with the prototype
cannula over 6-hour test period in mock flow loop primed with bovine blood. Complete
blood chemistry and plasma free hemoglobin did not vary significantly from baseline
values over the entire test period. The prototype was fabricated from PYC and has ‘open’
tip profile, the same design that was favored by the static loop tests. This prototype also
had the smallest diameter (7mm) of any cannula tested in all experiments therefore
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subjecting the blood to the highest resistance of any of the designs. Even under these
conditions the prototype showed excellent biocompatibility. This biocompatility could
also be amplified if incorporated with the Forcefield surface alteration in future studies.

Limitations
The main limitation for this study that arise are unrelated to the device or
experimental procedure, and mainly lie in the variability of the blood samples. Due to the
inherent variability in blood sources, performance of in vitro studies and subsequent
analysis and comparison of results can be problematic. For example, different species
blood (human vs. animals) used for testing thrombogenicity show differences in
mechanical fragility and rheological behavior (44).
The use of the HeartMate II VAD device requires anticoagulation, in this case
heparin, to prevent possible clotting and thrombus growth inside the pump. Typical
clinical application of the cannula in AVB does not use anticoagulation therapy
following implantation. The HeartMate II was also only run at one fixed pump speed
setting (8400rpm), creating a static flow for the duration of the experiment so the effects
of blood being subjected to more physiological-like conditions was not possible. More
accurate testing environment would include dynamic pressure and flow changes,
representing the systolic and diastolic pressures.
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FIGURE 43 – Cross sectional view of the HeartMate II. Blood in the experiment
were in contact with the small clearances inside the pump and may affect the results of
the trauma study.

The HeartMate II has small clearances and two rotor bearings that contact the
blood; Figure 43 shows a cross sectional view of the device. Some results from this
study, specifically the changes in the bloodwork and plasma free hemoglobin, may have
been the product of the HeartMate II rather than the implementation of the cannula.
Clinical investigations have reported minimal (< 30 mg/dl) hemolysis using these
devices, though continued investigation of blood trauma associated with rotary pumps is
ongoing.

Dynamic Loop Testing
The three cannulas tested in the adult circulation mock flow loop have provided a
key insight to the minimal cannula diameter size, 12mm, which will have a clinical
impact in treating aortic stenosis. The 36Fr cannula (12mm diameter) shows much better
performance than the two smaller cannulas tested. The study also has shown the
performance of the preliminary prototype (7mm diameter) is too poor for clinical usage
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in the AVB system. The relative % conduit flow of the 36Fr cannula, 59%, is comparable
to those in current clinical use for AVB and shows an improvement of 30mmHg in the
valve gradient for the severe AS case.

Limitations
To minimize measurement errors, post-calibrations were recorded for all pressure
and flow measurements to obtain linear gain and offset calibration factors. The flow loop
also used mechanical valves for the mitral, aortic, and the 19mm valve used in the AVB
system. These valves create a ‘ringing’ effect that can be seen in the waveforms, this can
be especially seen in the AoP signal in the sample plots in Appendix II. This effect
distorts part of the pressure waveform immediately following the closing of the valve.
Comparing data using these valves to in vivo data could be flawed. Though data is
averaged and peak beat-to-beat waveform data is inspected for each file, minimizing the
possible error. Despite the limitations, this study provides vital information on the effect
of cannula size on flow performance.

Continuous Flow Dynamics Testing
The analysis concluded that flow rate and wall shear stress increase with the
addition of sideholes. Increasing the size of the sideholes decreases the shear stresses and
increases flow. All wall shear stresses were significantly lower (maximum value from all
designs was 220 dynes/cm2) than the threshold for hemolysis (1500 dynes/cm2) and
platelet activation levels. Flow was shown to be turbulent for all cannulas tested with
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Reynolds values being slightly greater than 3,000. The highest flow conditions were seen
with the cannula with no sideholes and the cannula with large sideholes.
The cannula without sideholes showed the best blood biocompatibility in terms of
ideal wall stress magnitude and area. Due to safety issues, sideholes are an important
addition to the design. Increasing the number of sideholes may increase flow, but my also
lead to areas of low shear stress near the tip, which may lead to thrombus formation. In
vitro and/or in vivo studies are needed to further investigate these effects.

Limitations
The steady flows used in both studies do not represent the average flow rate
through the cannula and only represent the flow rate during systole. Physiologic pulsatile
flow may affect the velocity profiles and, therefore, the comparisons among cannula. The
pressure boundary assumption was based upon a clinical median value, which averaged
from 3 different sizes of cannula and represents the entire conduit as opposed to just the
cannula. A different boundary pressure may be more accurate than the 6 mmHg used in
these simulations. The prosthetic valve in the conduit may create more resistance than the
cannula and it is uncertain what the true pressure difference is for the cannula only.
This computational flow analysis also does not account for the left ventricular
geometries that may play a role in flow characteristics. There are two paths for blood to
take in this system, the aortic valve and the AVB conduit, and the shape of the ventricle
may have a role in the split of flow through each.
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Summary of Experimental Results
The cannula studies performed have aided in the development of the
specifications for a design of an apical cannula. In early investigations, the prototype
design was fabricated as a potential AVB therapy. Results from the static loop testing and
specifically the dynamic loop testing proved this design to be a poor choice for
application in AVB system. However, the insights learned from these studies have
contributed to a design of a new apical cannula presented in the next in Section X. Table
XV provides a summary of the results from experiments performed.

TABLE XV
SUMMARY OF RESULTS FROM EXPERIMENTAL STUDIES

Test

Result
Resistance to flow decreases with increasing cannula diameter

Static Flow Loop

Blood Trauma

Design that features an open distal oriface and sideholes along the
tip of the body favored over three designs tested
Preliminary Prototype fabrication material shows good
biocompatibility
No significant hemolysis or blood damage due to cannula
Preliminary Prototype developed not large enough for clinical
improvement of AVB

Dynamic Flow Loop

Flow rate and % conduit flow increases with cannula diameter size
12mm diameter tip (36Fr) smallest cannula whose % conduit flow
matches clinical data for currently used AVB systems

CFD Analysis

Flow rate and shear stresses influenced by number and size of
sideholes
Wall shear stress below threshold for hemolysis damage and
platelet activation for all designs

97

These experiments have given insight for specifications of a cannula design specifically
for three main design points: 1) Cannula Size, 2) Biocompatibility, 3) Tip Characteristics.

1. Cannula Size – The dynamic loop testing showed that the preliminary prototype
was not large enough to be an effective treatment for AVB. The dynamic and
static loop testing both showed a critical point in flow characteristics between
10mm and 10.7mm (30Fr and 32Fr) where the resistance increases dramatically.
This is also supported by the cannula manufacturer pressure vs. flow rate data.
Data from both experiments suggest using cannula 10.7mm in outer diameter or
larger.

2. Biocompatibility – The preliminary prototype showed good biocompatibility for
use of pyrolytic carbon as a fabrication material. Both the blood trauma mock
loop and CFD analysis show no hemolysis and minimal to no platelet activation.
Future application of the Forcefield technology will also greatly increase the
biocompatibility of the cannula.

3. Tip Characteristics – Static flow loop showed a design that incorporated an open
orifice at the distal tip with sideholes was favored over other designs studied. The
CFD analysis show flow rate increased with addition of sideholes while
increasing the size of the sideholes decreased the shear stresses. Turbulent flow
was also seen to dominate the flow during systole in all simulations.
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X.

FINAL APICAL CANNULA DESIGN

The results of the experiments have led to the final proposed design for an apical
cannula. The cannula and model for the AVB system are now presented.

Apical Cannula Design
The final design for the apical cannula was developed from the results of
experiments performed in this thesis work. The cannula consists of a 12mm (36French)
outer diameter opening with an open tip design shown in Figure 44.

Figure 44 – Apical cannula design developed from mock loop studies created with CAD
software (SolidWorks SP3.0, Dassault Systèmes). The selected criterion includes a 12mm
(36Fr) outer diameter, an open tip design, and is fabricated from pyrolytic carbon. All
units are in millimeters. Upper Left - Sectioned Side view, Lower Left – Top view,
Lower Right – Right Sided view, Upper Right – 3D rendered drawings.
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The tip of the cannula is 12mm in diameter, which adapts to a larger 17mm at the
base of the cannula where it attaches to the conduit material. There is a small 0.5mm
engraved ring at the base of the 17mm section of the cannula so that graft material may
be sewn onto the cannula. The light 0.1mm etchings are cosmetic and intended to assist
the surgeon with implantation. In a blood-soaked operation field, the etchings give a
tactile feel to the cannula and can aide in implantation so the surgeon can know how far
the cannula is inside the apex of the left ventricle.
The tip characteristics have a straight, open orifice at the proximal tip with eight
sideholes arranged offset in two rows. These openings also feature rounded edges and are
smooth to improve biocompatibility and flow characteristics. The size and number of
sideholes on the cannula are the same as medium, eight sideholes model studied in the
CFD analysis. The proposed cannula is the same cannula model used in the CFD studies.
Appendix IV gives the results report of CFD analysis of this model.
The fabrication of the apical cannula will be identical to that used on the
preliminary prototype. The thickness of the pyrolytic carbon is based from proprietary
fabrication methods. The cannulas studied in static and dynamic mock flow loops all had
wall thicknesses slightly larger than 1mm. The proposed apical cannula has a wall
thickness of 1.3mm.

Aortic Valve Bypass System
The proposed AVB system consists of the apical cannula connected to a right
angle bend adapter, graft material, and mechanical valve shown in Figure 45. The apical
cannula has a 12mm tip (36Fr) that widens to 17mm at the base. The cannula connects to
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17mm Dacron graft material wire reinforced to conform to a right angle bend. This
conduit has a 17mm pyrolytic mechanical valve. The conduit is 80mm in length, which is
the best approximation for the distance between the left ventricular apex to the
descending aorta in an average patient.

FIGURE 45 – Proposed design for the AVB system. The apical cannula adapts
into a right bend adaptor and into a size 17mm Dacron graph. The valve intended for use
is a mechanical valve also sized to 17mm. This model was designed through use of CAD
software (SolidWorks SP3.0, Dassault Systèmes) and used in CFD analysis.
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Closing Comments
This thesis has presented the possible advantages that aortic valve bypass has over
aortic valve repair in high risk patient groups. The experiments performed have been used
to develop a new design for the apical cannula component in the aortic valve bypass
system. This incorporates new technologies, techniques, and fabrication materials. The
‘forcefield’ technology and Seldinger insertion technique are exciting prospects to make
this design feasible for market development.
Aortic valve bypass results in a low gradient across the native stenotic valve and a
small gradient across the conduit. The results from the mock loop experiments, CFD
analysis, clinical data, and findings from other researchers have aided in the creation of a
new apical cannula. It is hoped that this design will be a more favorable design over
currently used apical connectors. Further studies are needed to validate this design.

Future Work
Future work on this system would include experimental analysis on the proposed
cannula. It will need to be fabricated and tested against currently available cannula and
apical connectors using methods similar to this thesis work. In vivo animal model studies
would aide in biocompatible and ultimate efficacy of the AVB system. In addition, future
studies may further investigate the shape of the sideholes. For this study only oval shaped
sideholes with 0.5mm fillet were studied. There may be alternate geometries that could
improve flow characteristics.
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1. File Report
Table 1. File Information for CFX
Case

CFX

File
Path

C:\Users\Joel\Desktop\36Fr_straight_tip_17mm_4Hole_new_files\dp0\CFX\CFX\CFX_
037.res

File
Date

02 December 2010

File
Time

05:58:51 PM

File

CFX5
111

Type
File
Versio 12.0
n
2. Mesh Report
Table 2. Mesh Information for CFX
Domain

Nodes Elements

Default Domain 149169 814855
3. Physics Report
Table 3. Domain Physics for CFX
Domain - Default Domain
Type

Fluid

Location

B1117

Materials
Blood
Fluid Definition

Material Library

Morphology

Continuous Fluid

Settings
Buoyancy Model

Non Buoyant

Domain Motion

Stationary

Reference Pressure

1.0000e+00 [atm]

Turbulence Model

k epsilon

Turbulent Wall Functions Scalable
Table 4. Boundary Physics for CFX
Domain Boundaries
Boundary - Inlet 1
Type

INLET

Location

F1118.1117, F1132.1117, F1133.1117

Settings
Default
Domain Flow
Direction

Zero Gradient

Flow Regime Subsonic
Mass And
Momentum

Static Pressure
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Relative
Pressure

5.0000e+01 [mm Hg]

Turbulence

Medium Intensity and Eddy Viscosity Ratio

Boundary - Outlet
Type

OUTLET

Location

F1177.1117

Settings
Flow Regime Subsonic
Mass And
Momentum

Static Pressure

Relative
Pressure

4.4000e+01 [mm Hg]

Boundary - Default Domain Default
Type

WALL

Location

F1119.1117, F1120.1117, F1121.1117, F1122.1117, F1123.1117,
F1124.1117, F1125.1117, F1126.1117, F1127.1117, F1128.1117,
F1129.1117, F1130.1117, F1131.1117, F1134.1117, F1135.1117,
F1136.1117, F1137.1117, F1138.1117, F1139.1117, F1140.1117,
F1141.1117, F1142.1117, F1143.1117, F1144.1117, F1145.1117,
F1146.1117, F1147.1117, F1148.1117, F1149.1117, F1150.1117,
F1151.1117, F1152.1117, F1153.1117, F1154.1117, F1155.1117,
F1156.1117, F1157.1117, F1158.1117, F1159.1117, F1160.1117,
F1161.1117, F1162.1117, F1163.1117, F1164.1117, F1165.1117,
F1166.1117, F1167.1117, F1168.1117, F1169.1117, F1170.1117,
F1171.1117, F1172.1117, F1173.1117, F1174.1117, F1175.1117,
F1176.1117, F1178.1117

Settings
Mass And
Momentum

No Slip Wall

Wall
Roughness

Smooth Wall

4. Solution Report
Table 5. Boundary Flows for CFX
Location

Type

Mass Flow

Momentum
X

Y

Z

Default Domain Default Boundary 0.0000e+00 2.0251e-05 -2.5772e-01 8.6553e-05
Inlet 1

Boundary 3.9935e-02 1.4347e-04 -7.2421e-01 2.9014e-04
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Outlet

Boundary -7.0625e-02 -2.8056e-06 9.7880e-01 -1.7091e-06

Table 6.
Average Velocity

Max Velocity

Min Velocity

1.868e-02 [m s^-1]

4.994e-02 [m s^-1]

4.261e-03 [m s^-1]

Outlet 3.912e-01 [m s^-1]

4.502e-01 [m s^-1]

3.589e-01 [m s^-1]

Inlet

Flow
Inlet

Flow [liter^1 min^-1]

1.123e-04 [m^3 s^-1] 6.741e+00

Outlet 6.344e-05 [m^3 s^-1] 3.806e+00

Reynolds Number
Outlet 3.096e+03
Figure 1.
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Figure 2.

Figure 3.
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Figure 4.

Figure 5. Inside wall shear stress
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Figure 6. Outside wall shear stress

Figure 7.
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Figure 8.

Figure 9.
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Figure 10.

5. User Data
Table 7.
Wall Shear Stress

Average

Max

Min

Default Domain Default 2.973e-02 [mm Hg] 1.444e-01 [mm Hg] 1.175e-05 [mm Hg]
Shear Strain Rate

Average

Default Domain Default 1.876e+02 [s^-1]

Max

Min

8.514e+02 [s^-1]

1.594e+00 [s^-1]

Volume
Default Domain

3.668e-05 [m^3]

Area
Inlet 1

6.015e-03 [m^2]

Outlet

1.622e-04 [m^2]

Default Domain Default 3.212e-03 [m^2]
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Figure 11.
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